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Triple-negative breast cancer (TNBC) is a subtype of breast cancer for which no 
approved targeted therapy is available, and chemotherapy is the mainstay of the 
treatment for these patients. Administration of various chemotherapies can be limited 
by toxicities and the development of tumour resistance and the median overall 
survival of these patients is low. This research aimed at studying the efficacy of 
epimers of ginsenoside Rg3 (Rg3), 20(S)-Rg3 (SRg3) and 20(R)-Rg3 (RRg3), in 
inhibition of cancer growth and angiogenesis for the potential treatment of this 
disease. The preliminary molecular docking studies predicted that Rg3 interacted well 
with aquaporin 1 (AQP1), which plays important roles in cancer progression.  
First, stereoselectivity of Rg3 epimers was shown in inhibition of proliferation, 
migration and invasion of TNBC cell lines and blocking AQP1 water channel. Due to 
this stereoselectivity, the combination of both epimers was optimised for inhibition of 
loop formation in endothelial cells, using response surface methodology (RSM). It was 
shown that this optimised combination, referred to as C3, significantly inhibited the 
proliferation and migration of human and murine endothelial cells. Rg3 epimers 
worked as allosteric modulators of vascular endothelial growth factor receptor 2 
(VEGFR2). C3 decreased the expression of VEGF and significantly decreased the 
expression of AQP1 and the phosphorylation of proteins downstream of AKT 
signalling in hypoxic and normoxic conditions.  
In TNBC monolayer cultures, C3 significantly decreased cell migration but did not 
inhibit cell proliferation. In TNBC mammospheres, C3 decreased mammosphere 
formation efficiency, with no significant reduction in cell viability. C3 decreased the 
expression of CD44 and the ratio of CD44/24. C3 also decreased the function of cells 
via affecting the proteins downstream of activation of the mammalian target of 
rapamycin (mTOR). In molecular docking, Rg3 epimers showed good binding scores 
with VEGFR2 and insulin growth factor-1 receptor amongst the tested tyrosine kinase 
receptors. Rg3 epimers also showed a good binding score with rapamycin-binding site 
of mTOR and activator of mTOR, Rheb. In a mouse model of metastatic TNBC, when 
an extrapolated dose of C3 (23 mg/kg SRg3 + 11 mg/kg RRg3) or an escalated dose (46 
mg/kg SRg3 + 23 mg/kg RRg3) was injected into mice, a significant reduction in the 
primary tumour volume and decreased load of metastasis in the lungs was noticed. 
Furthermore, the number of affected axillary lymph nodes was significantly reduced. 
Since Rg3 is prone to extensive metabolism in vivo, the efficacy of deglycosylated 
metabolites of Rg3 epimers was also studied. It was shown that these metabolites were 
inhibitors of cell proliferation in TNBC and endothelial cells. The mechanism for this 
action was induction of necroptosis/necrosis in TNBC cell lines and apoptosis in 
endothelial cells. Among the tested metabolites, 20(S)-ginsenoside Rh2 (S-Rh2) 
showed the best inhibition of loop formation, and allosteric modulatory action on 
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VEGFR2. It was also predicted to be a good blocker of the AQP1 water channel. 
Altogether, the findings of this project show the possibilities of Rg3, as a potential 
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Chapter 1 Introduction and Literature Review 
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer, with 
higher prevalence in women < 50 years old, a higher probability of relapse and poorer 
overall survival. Due to the lack of targeted therapy for this subtype of breast cancer, 
patients have fewer treatment options available. The treatment is limited to 
chemotherapy, the application of which is usually limited by toxicities and 
development of drug resistance. This thesis aimed at studying a new treatment option 
for these patients, ginsenoside Rg3 (Rg3). Rg3 is extracted from a traditional herbal 
medicine, Panax ginseng, which has been used by humans safely for thousands of years. 
Rg3 is one of the most pharmacologically important molecules extracted from this 
plant. Several studies focused on the anticancer effects of Rg3. Rg3 has two structurally 
related epimers; 20(S)-Rg3 (SRg3) and 20(R)-Rg3 (RRg3).  
This thesis reports studies on the potential of Rg3 epimers as a treatment for TNBC. 
The thesis includes 6 chapters. Chapter 1 presents an in-depth review of the literature 
on the anti-cancer and anti-angiogenic properties of Rg3 epimers and the druggable 
targets in TNBC. Chapter one of this thesis includes 3 review papers. The first review 
paper comprehensively studied and categorised the efficacy of each of the epimers as 
anticancer agents, focusing on mechanisms of action of these molecules, their 
application in combination with chemotherapy treatments, the pharmacokinetics of 
these molecules and outcomes of clinical trials on Rg3. The review also discusses the 
potential of Rg3 as a blocker of the water transport function of AQP1, which plays 
important roles in cancer progression and discusses the potential of Rg3 as a treatment 
for TNBC.  
The next review paper focused on the anti-angiogenic properties of Rg3 epimers and 
for the first time discussed the controversies in the literature regarding the anti- or pro-
angiogenic effects of Rg3. The paper also described pharmacodynamics of action of 
Rg3 as an anti-angiogenic drug and summarised the evidence on the anti-angiogenic 
actions of Rg3, in vitro and in vivo. 
The third review paper discussed druggable targets in TNBC patients, to bring insight 
into the current status of the disease and ongoing clinical trials on these patients. The 
paper also summarised the promising molecular targets at preclinical and phase I 
clinical trial stages. 
Chapter 2 focuses on the specific functions of each epimer in TNBC and shows the 
stereoselectivity of Rg3. Based on these results, in chapter 3, the concentrations of SRg3 
and RRg3 were optimised in combination for anti-angiogenic action and some 
mechanisms of the action of this combination were studied. In chapter 4, it was shown 
that this combination was optimised for its anti-cancer action in TNBC in vitro models 
and mechanisms of anti-cancer actions of this combination were suggested. 
Furthermore, the combination was tested in vivo in a metastatic breast cancer mouse 
 
 2 
model. Rg3 is prone to deglycosylation and producing active metabolites. In chapter 
5, differential anti-cancer potential of these metabolites is investigated. Chapter 6 
summarises the significance of the findings and proposed future studies. 
 
1.1 Publications arising from this thesis 
The research conducted in this thesis led to several publications in well-known peer-
reviewed journals. Some of them are still under review for possible publication in high 
impact journals. The following is the list of papers published and those still under 
review for publication: 
Nakhjavani, M., Hardingham, J. E., Palethorpe, H. M., Tomita, Y., Smith, E., Price, T. 
J., and Townsend, A. R. (2019). Ginsenoside Rg3: Potential molecular targets and 
therapeutic indication in metastatic breast cancer. Medicines, 6(1), 17. 
Nakhjavani, M., Smith, E., Townsend, A. R., Price, T. J., and Hardingham, J. E. (2020). 
Anti-Angiogenic Properties of Ginsenoside Rg3. Molecules, 25(21), 4905. 
Nakhjavani, M., Hardingham, J. E., Palethorpe, H. M., Price, T. J., and Townsend, A. 
R. (2019). Druggable molecular targets for the treatment of triple negative breast 
cancer. Journal of Breast Cancer, 22(3), 341. 
Nakhjavani, M., Palethorpe, H. M., Tomita, Y., Smith, E., Price, T. J., Yool, A. J., Pei, J. 
V., Townsend, A. R., and Hardingham, J. E. (2019). Stereoselective anti-cancer activities 
of ginsenoside Rg3 on triple negative breast cancer cell models. Pharmaceuticals, 12(3), 
117. 
Nakhjavani, M., Smith, E., Yeo, K., Palethorpe, H. M., Tomita, Y., Price, T. J., 
Townsend, A. R., and Hardingham, J. E. (2021) Anti-angiogenic properties of 
ginsenoside Rg3 epimers: in vitro assessment of single and combination treatments. 
Cancers, 13(9), 2223. 
Nakhjavani, M., Smith, E., Palethorpe, H. M., Tomita, Y., Yeo, K., Price, T. J., 
Townsend, A. R., and Hardingham, J. E. Anti-cancer effects of an optimised 
combination of ginsenoside Rg3 epimers on triple negative breast cancer models. 
Submitted to Pharmaceuticals (under revision). 
Nakhjavani, M., Smith, E., Yeo, K., Tomita, Y., Price, T. J., Yool, A. J., Townsend, A. R., 
and Hardingham, J. E. (2021) Differential anticancer activities of the active metabolites 
of ginsenoside Rg3. Accepted for publication in Journal of Ginseng Research. 
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1.2 Conference presentations arising from this thesis 
This research was presented at well-known and peer-reviewed conferences and was 
awarded in some of them, as listed below: 
Nakhjavani, M., Smith, E., Price, T. J., Townsend, A. R., and Hardingham, J. E. 
Ginsenoside Rg3 enantiomers in a defined ratio as a novel treatment for metastatic 
triple negative breast cancer. Poster presentation at San Antonio Breast Cancer 
Symposium, 2020 (virtual).  
Nakhjavani, M., Smith, E., Price, T. J., Townsend, A. R., Hardingham, J. E. Ginsenoside 
Rg3 enantiomers in a defined ratio as a novel treatment for triple negative breast 
cancer. Oral presentation in TQEH Research Day 2020, SA, Australia. 2020. 
Nakhjavani, M., Smith, E., Price, T. J., Townsend, A. R., Hardingham, J. E. Ginsenoside 
Rg3, a potential novel treatment for metastatic breast cancer. Poster presentation in 
Florey's Postgraduate Research Conference, SA, Australia. 2020. Awarded for Innovation 
and Commercial Partners Prize 
Nakhjavani, M. Palethorpe, H. M., Tomita, Y., Smith, E., Price, T. J., Townsend, A. R., 
Hardingham, J. E. Novel candidates for the treatment of metastatic breast cancer. Oral 
presentation in Adelaide Pharmacology Group (APG) Meeting. 2019. SA, Australia. 
Nakhjavani, M. Palethorpe, H. M., Tomita, Y., Smith, E., Pei, J. V., Price, T. J., Yool, A. 
J., Townsend, A. R., Hardingham, J. E. Anti-cancer properties of ginsenoside Rg3 
epimers. Mini-oral presentation in TQEH Research Day 2019, SA, Australia. 2019. 
Awarded for best mini-oral presentation. 
Nakhjavani, M., Palethorpe, H. M., Tomita, Y., Smith, E., Yool, A. J., Townsend, A. R., 
Hardingham, J. E. Comparison of the molecular modelling of bacopaside I and 
bacopaside II, candidate anti-angiogenic agents, with sorafenib. Oral presentation in 
ASMR SA Scientific Meeting. 2018. SA, Australia. 
Nakhjavani, M., Palethorpe, H. M., Tomita, Y., Smith, E., Price, T. J., Yool, A. J., 
Townsend, A. R., Hardingham, J. E. Ginsenoside Rg3; an anti-invasion candidate for 
triple negative breast cancer. Poster presentation in Florey's Postgraduate Research 
Conference. SA, Australia. 2018. 
Nakhjavani, M., Palethorpe, H. M., Tomita, Y., Smith, E., Price, T. J., Yool, A. J., 
Townsend, A. R., Hardingham, J. E. 20(S)-ginsenoside Rg3; an anti-invasive candidate 






1.3 Awards and prizes 
This research received the following awards and prizes: 
Innovation and Commercial Partners Prize, Florey's Postgraduate Research 
Conference 2020 
The Doctor Chun Chung Wong and Madam So Sau Lam Memorial Postgraduate 
Cancer Research Top-Up Scholarship, 7000 AUD (2019) 
Nominated as one of the 50 women of impact and influence, University of Adelaide 
(2019) 
Best mini-oral presentation, TQEH Research Expo, Adelaide (2019) 
 
1.4 Thesis Format 
This thesis is based on the collection of the manuscripts produced during the course 
of the research and has been submitted according to the format approved by the 
University of Adelaide. The thesis is provided and available in both hard and soft copy 
which are identical. The soft copy is available online at the University of Adelaide 
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Chapter 2 Stereoselective activity of the epimers of ginsenoside Rg3 
2.1. Background 
 As reviewed in the previous chapter, the role of Rg3 had been investigated in 
several cancer models. Rg3 is extracted from any part of the plant Panax ginseng, but 
the most important and common part is the root. The extraction procedure usually 
includes heating up the ginseng root, which raises the production of several members 
of the ginsenoside family of saponins, Rg3 being one of them. Depending on the 
extraction conditions, such as temperature and pressure, the ratio of Rg3 epimers 
changes. A big concern with reviewing the efficacy of Rg3 published in the literature 
was that in numerous studies, Rg3 was extracted in experimental settings and without 
further specification of the extracted epimer or mixture of epimers, or the purity of the 
molecule extracted, was studied in vitro and in vivo. As mentioned in several papers 
reviewed in chapter one, Rg3 epimers showed stereoselectivity action in interaction 
with ion channels, inhibition of epithelial-mesenchymal transition, antioxidant effect 
and promoting immune function. Due to this stereoselective action, it is very 
important to identify the exact molecule that is being studied. In the current chapter, 
continuing with the search for a better treatment for TNBC, anti-cancer effects of each 
Rg3 epimer were evaluated and stereoselectivity of epimers was shown.  
As reviewed in the previous chapter, AQP1 is highly expressed in TNBC and its 
expression is correlated with higher tumour grade, poorer prognosis and overall 
survival of these patients. In this paper, using in silico molecular docking studies, the 
interaction of Rg3 with AQP1 water channel was studied. Following promising results 
from this in silico study, an in vitro assay was performed to show the interaction of Rg3 
with AQP1 water channel, using oocyte swelling assay. 
SRg3-specific blockage of AQP1 was an important finding, leading to further 
experiments on TNBC cell lines. The experiments showed that only SRg3 inhibited the 
proliferation of MDA-MB-231, a mesenchymal-like TNBC cell line. However, it was 
only RRg3 that inhibited the invasion of these cells in a spheroid invasion assay. The 
epimers also differently inhibited the migration of MDA-MB-231 in circular scratch 
wound closure and in transwell migration assays. These findings in TNBC models 
confirmed the stereoselective activities of Rg3.  
The findings of this chapter showed the potential of Rg3 epimers as a treatment for 
TNBC. It also paved the way for optimisation of the combination of both epimers, 
which is the topic of chapter 3. 
This chapter has been published as: 
Nakhjavani, M., Palethorpe, H. M., Tomita, Y., Smith, E., Price, T. J., Yool, A. J., Pei, J. 
V., Townsend, A. R., and Hardingham, J. E. (2019). Stereoselective anti-cancer activities 
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of ginsenoside Rg3 on triple negative breast cancer cell models. Pharmaceuticals, 12(3), 
117. 
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Chapter 3 Effects of ginsenoside Rg3 on angiogenesis 
3.1. Background 
Cancer angiogenesis is a complex but highly regulated and organised process, which 
fulfils a tumour's nutritional requirements and facilitates tumour cells' metastasis to 
other organs. Some tumours, including breast, show high levels of angiogenesis, hence 
the administration of anti-angiogenic drugs became a part of cancer treatment 
regimens for these tumours. However, the administration of the current clinically 
approved anti-angiogenic treatments is accompanied by serious side effects and drug 
resistance. Therefore, drug development programs are actively ongoing to introduce 
safer and more effective drugs. 
As described in the first chapter, one important aspect of the anti-cancer efficacy of 
Rg3 is its anti-angiogenic action. Blood vessels have a single layer of endothelial cells. 
These cells, via proliferation, migration and invasion are responsible for angiogenesis. 
Hence, an important part of preclinical in vitro assessment of anti-angiogenic 
candidates focuses on their efficacy in inhibiting these critical steps of angiogenesis in 
these cells.  
As discussed before, AQP1 is highly expressed in endothelial cells and promotes 
angiogenesis. Blockers of AQP1 have shown anti-angiogenic properties. In the first 
chapter, anti-angiogenic properties of Rg3 were reviewed and in chapter 2, it was 
shown that SRg3 blocked AQP1 water channel. Based on these and the stereoselective 
efficacy of Rg3 epimers, for the first time, I have shown the anti-angiogenic efficacy of 
an optimised combination of SRg3 and RRg3. The optimisation of the SRg3 and RRg3 
combination was found using response surface methodology (RSM) modelling based 
on loop formation assay. Loop formation assay is an in vitro measurement of 
angiogenesis, which takes into account both the migration and invasion of endothelial 
cells.  
To evaluate the anti-angiogenic efficacy of Rg3, human and murine endothelial cells 
were used. This would also give an estimation about the sensitivity of human or mouse 
tumours to the applied drug, and of use in the mouse model of breast cancer. The 
combination was also tested in migration and proliferation assays to confirm the 
efficacy of the drug candidate. The mechanism of inhibition of proliferation and mode 
of cell death was studied. 
VEGF, the expression of which is increased in hypoxic conditions, is one of the crucial 
pro-angiogenic factors and its interaction with VEGFR2 is the key driver of 
angiogenesis. Therefore, to further study the mechanisms of the drug, the effect of Rg3 
on this interaction was studied in silico and in vitro. In addition, the effect of the drug 
on the signalling of PI3K/AKT, and expression of AQP1 and FAK was studied. Since 
hypoxia is one of the important conditions that encourages angiogenesis, these 
mechanisms were studied in both normoxia and hypoxia. 
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This chapter was submitted to the "Angiogenesis" journal and is currently under review. 
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3.2. Statement of Authorship 
 








3.3. Anti-angiogenic properties of ginsenoside Rg3 epimers: in vitro assessment of single and combination treatments 
 
 





























































To perform the circular wound migration assay, HUVECs, 2H-11, and 3B-11 cells, 
either not pretreated or pretreated for 3 days with Rg3 epimers, were seeded in 96-
well plates at 3.5 × 104, 1.2 × 104, and 4 × 104 cells per well, respectively, and were 
incubated overnight. Then, to inhibit cell proliferation, the cells were exposed with 
culture media containing 2% FBS and 1 µg/mL mitomycin C and incubated overnight. 
The following day, when a confluent monolayer was achieved, circular wounds were 
made using suction through a sterile p10 pipette tip. Using ImageJ software (version 
1.53a, National Health of Institute, Bethesda, MD, USA), the area of each circular 
wound was measured at two timepoints, based on a time of 0 and 10 h (murine 
endothelial cells), or 16 h (HUVEC). Cell migration was calculated for each well as a 
percentage of the initial wound area at time 0. The experiment included six replicates 














Chapter 4 Effects of ginsenoside Rg3 on triple negative breast cancer 
models 
4.1. Background 
As reviewed in chapter 1 and investigated in chapter 2, Rg3 epimers have potential to 
be studied as a treatment for TNBC and especially metastatic TNBC. TNBC has a high 
potential of developing metastasis and therefore, to inhibit metastasis, two general 
options are considered: (1) to inhibit angiogenesis and (2) to inhibit migration of cancer 
cells. Anti-angiogenic properties of Rg3 were reviewed in chapter 1 and further 
investigated in chapter 3. Given the stereoselective activities of Rg3 epimers, the 
efficacy of the combination of Rg3 epimers, C3, was evaluated in vitro in chapter 3, 
which provided further evidence of the potential of C3 for application in TNBC. 
The main question in this chapter was whether C3 had any efficacy on TNBC models. 
To answer this question, two TNBC cell lines were chosen, one derived from a 
metastatic site with more mesenchymal characteristics and one from a primary tumour 
with more epithelial characteristics. First, an RSM model was developed and the 
efficacy of C3 in TNBC cell migration in 2D and 3D models was evaluated. Then, to 
study the efficacy of this treatment in a more relevant model to human breast tumour, 
mammospheres were used. The efficacy of C3 on mammosphere formation and stem 
cell markers was studied. Stem cell markers studied in this research were CD44 and 
CD24, the ratio of which plays important roles in invasiveness of this disease and 
metastasis.  
Furthermore, using in silico molecular docking, a screening of interaction of Rg3 
epimers with a number of receptor tyrosine kinases was performed to find potential 
targets. Then, the effect of C3 on the PI3K/AKT signalling of TNBC mammospheres 
was studied using a protein array. Since the results indicated that C3 affected mTOR 
signalling, the interaction of Rg3 with rapamycin binding site of mTOR and Rheb, an 
activator of mTOR, was studied. Furthermore, it was investigated whether C3 affected 
the expression of AQP1 and FAK in TNBC mammospheres. 
Subsequently, the efficacy of C3 was evaluated in an in vivo orthotopic mouse model 
of metastatic TNBC. This model was based on using immunodeficient Nod scid gamma 
(NSG) mice, which are capable of growing human TNBC cells. An almost complete 
lack of immune system in this model and use of a highly metastatic cell line (MDA-
MB-231-Luc) makes this model a highly aggressive model, in which the cells 
spontaneously metastasise to distant organs. The growth of the primary and 
secondary tumours was monitored using IVIS spectrum. The dose of the drug was 
extrapolated from C3, based on the total body volume of water in an average mouse 
of 18 g. To bypass the first-pass effect, the drug was injected subcutaneously. 
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Following the promising results of the first animal study, a second dose-escalation 
study was designed and performed. 
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4.3. Anti-cancer effects of an optimised combination of ginsenoside Rg3 epimers on triple negative breast cancer models 
Article 
Anti-cancer effects of an optimised combination of ginsenoside Rg3 
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Abstract: Key problems of chemotherapies, as the mainstay of treatment for triple-
negative breast cancer (TNBC), are toxicity and development of tumour resistance 
leading to the low survival rate of these patients. Using response surface 
methodology (RSM), we previously optimised the combination of epimers of 
ginsenoside Rg3 (Rg3) for anti-angiogenic action. Here, we show that the optimised 
combination (C3), derived from an RSM model of migration of TNBC cell line MDA-
MB-231, inhibited migration of MDA-MB-231 and a second TNBC cell line, HCC1143, 
in 2D and 3D migration assays (p < 0.0001). C3 significantly inhibited mammosphere 
formation efficiency in both cell lines, while it did not cause significant cell death. The 
combination significantly decreased the CD44+ stem cell marker in the 
mammospheres. Molecular docking showed that Rg3 epimers had a better binding 
score with IGF-1R than with EGFR, HER-2 or PDGFR. In addition, this in silico 
screening predicted an mTOR inhibitory function of Rg3. C3 affected the signalling 
of AKT as phosphorylation of 4E-BP1, P70S6K, PTEN and RPS6 in MDA-MB-231 
mammospheres was decreased and phosphorylation of PRAS40, PTEN, Raf-1, RPS6 
and RSK1 was decreased in HCC1143. The combination was then tested in a mouse 
model of metastatic TNBC. A dose of 23 mg/kg SRg3 + 11 mg/kg RRg3 or an escalated 
dose of 46 mg/kg SRg3 + 23 mg/kg RRg3 was administered to NSG mice bearing 
MDA-MB-231-Luc cells. Calliper and IVIS spectrum measurement of the primary and 
secondary tumour showed that the treatment shrunk the primary tumour and 
decreased the load of metastasis in mice. In conclusion, this combination of Rg3 
epimers showed promising results as a potential treatment option for TNBC patients.  
Keywords: Ginsenoside Rg3, Epimer, Triple negative breast cancer, Metastasis, 
Response surface methodology, Nod scid gamma mice 
 
1. Introduction 
Triple-negative breast cancer (TNBC) is a subtype of breast cancer for which 
limited targeted therapy is available. Chemotherapy is the mainstay of the treatment 
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for TNBC. Administration of various chemotherapies can be limited by toxicities and 
the development of tumour resistance [1]. Despite using selected chemotherapy 
regimens, these patients have a higher rate of developing visceral metastases [2] with 
a median overall survival of 13.3 months [3].  
Cancer cells undergo epithelial to mesenchymal transition (EMT), and acquire 
cancer stem cell characteristics [4], one of the mechanisms by which cells become 
resistant to chemotherapies (reviewed in [5]). Different subtypes and stages of breast 
cancer have their unique expression of stem cell markers such as CD44, CD24 and 
aldehyde dehydrogenase (ALDH) [4, 6] and the search for drugs which reduce cancer 
stemness is an essential investigation in drug discovery and development programs. 
Phosphatidylinositol 3-kinase /protein kinase B/mammalian target of rapamycin 
(PI3K/AKT/mTOR) pathway is one of the several self-renewal pathways existing in 
breast cancer cells [4] and inhibitors of this pathway may reduce ‘stemness’ of cancer 
cells. Targeting this pathway is therefore important in overcoming drug resistance [7, 
8], cell survival, and metastasis in this cancer [9, 10]. Several clinical studies are 
ongoing to evaluate the efficacy of the inhibitors of this pathway in TNBC patients 
(reviewed in [11]). 
Natural products have always been a major source of therapeutic drugs. About 
70% of the current cancer treatments are derived from or imitate natural products [12]. 
Natural inhibitors of PI3K/AKT signal transduction pathway have been under 
investigation for the treatment of breast cancer [13]. Ginsenoside Rg3 (Rg3) is a 
member of the ginsenosides family of molecules extracted from Panax ginseng. The 
molecule has two epimers, 20(S)-Rg3 (SRg3) and 20(R)-Rg3 (RRg3). We have 
previously discussed the potential of these molecules as a treatment for metastatic 
breast cancer [14, 15]. Besides, studies showed that Rg3 decreased the activation of 
PI3K/AKT pathway in several tumour models such as leukemia, ovarian, and lung 
carcinoma (reviewed in [14]). Based on this background, Rg3 might be a potential 
candidate for the treatment of metastatic TNBC (mTNBC). We previously showed that 
the epimers of Rg3 have stereoselectivity in their anti-cancer actions [16] such that only 
SRg3 inhibited the proliferation of MDA-MB-231 and blocked aquaporin 1 (AQP1) 
water channel, which plays important roles in the proliferation, migration, and 
invasion of cancer cells and in angiogenesis. Furthermore, it was only RRg3 that 
inhibited the invasion of MDA-MB-231 cells. SRg3 and RRg3 inhibited the migration 
of TNBC cells in wound closure and transwell migration assays with different manners 
[16]. Based on these findings, SRg3 and RRg3 could be considered as two different 
drugs. Therefore, we determined the optimal concentration of SRg3 and RRg3 using 
response surface methodology (RSM) modelling. RSM is one of the well-established 
methods of studying drug combinations which is especially important and helpful in 
cancer treatment studies [17-19]. The optimisation, which was based on the anti-
angiogenic effects of the molecules [20], showed that a combination of 50 µM SRg3 + 
25 µM RRg3 had the best efficacy in inhibition of loop formation and cell migration of 
endothelial cells. This treatment induced cell death and cell cycle arrest in human and 
murine endothelial cell lines, decreased the expression of vascular endothelial growth 
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factor (VEGF), AQP1 and phosphorylation of several proteins downstream of 
activation of AKT.  
The current study aimed at investigating the efficacy of this combination on TNBC 
cell lines and in a murine model of mTNBC. The optimised combination of both 
molecules was assessed using RSM to confirm that the combination is effective in 
inhibiting TNBC cell migration. Next, the efficacy of the treatment was studied on 
mammospheres, as a more relevant model of human breast tumour and the effects of 
the treatment on stem cell markers and PI3K/AKT signalling pathway was 
investigated. Lastly, the in vivo efficacy of the treatment was studied in an orthotopic 
model of murine mTNBC.  
2. Materials and Methods  
2.1. Materials 
SRg3 and RRg3 (both with a purity of > 98% by HPLC) were purchased from 
ChemFaces®, Wuhan, China. Stocks of SRg3 and RRg3 were prepared in dimethyl 
sulfoxide (DMSO D2650, HYBRI-MAX, Sigma-Aldrich, Steinheim, Germany) and 
stored at -20°C, as previously described [16]. TNBC cell lines; MDA-MB-231 (basal-like 
with mesenchymal or claudin-low phenotype) and HCC1143 (basal-like with 
epithelial phenotype) and MCF-12A (immortalised normal human breast epithelial 
cell line) were purchased from American type culture collection (ATCC). Luciferase-
expressing MDA-MB-231-Luc cells were purchased from CellBank Australia. All cells 
were mycoplasma-free. As previously described, cells were tested for mycoplasma 
using MycoAlert Detection Kit (Lonza) and/or a custom PCR-based assay [21, 22]. 
2.2. Cell culture of adherent cells 
MDA-MB-231 cells were grown in Dulbecco’s Modified Eagle Medium (DMEM; 
Life Technologies, CA, USA) and HCC1143 cells were grown in Roswell Park 
Memorial Institute (RPMI) 1640 medium (Life Technologies, Carlsbad, CA, USA). 
Media was supplemented with 10% foetal bovine serum (FBS; Corning, Corning, NY, 
USA) and 1% penicillin-streptomycin solution (Life Technologies). MCF-12A cells 
were grown in MammoCult™ media supplemented with 5% FBS (Corning), 10% 
MammoCult™ proliferation supplement, 0.5% hydrocortisone and 0.2% heparin (all 
from Stem Cell Technologies, Vancouver, Canada). MDA-MB-231-Luc cells were 
cultured in L-15 media supplemented with 15% FBS and 1% penicillin-streptomycin 
(Life Technologies). A week before the animal experiment, the cells were harvested, 
washed in Dulbecco's phosphate-buffered saline (DPBS, Gibco, Thermo Fisher 
Scientific, Waltham, MA, USA) and grown as mammospheres in MammoCult™ media 
(described below).  
2.3. Circular scratch migration assay 
The experiment was performed as previously described [16]. Briefly, three-day 
pre-treated MDA-MB-231 and HCC-1143 cells were seeded in 96-well cell culture 
plates (Corning® Costar®, Corning, NY, USA), at 4 × 104 and 8 × 104 cells/well, 
respectively. Following overnight incubation, a circular scratch was made on a 
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monolayer of cells and images at time 0 and 24 h were taken using a Nikon microscope. 
The migration (%) of the cells was measured based on the area of the circular wound 
measured with ImageJ software (version 1.53a, National Health of Institute, Bethesda, 
MD, USA). The experiment was replicated 6 times and results represented as mean ± 
standard deviation (SD). 
2.4. Response surface methodology (RSM) 
To confirm that the effective combination of Rg3 epimers on endothelial cells was 
effective on TNBC cells, an RSM model was developed for the migration of MDA-MB-
231, as previously described (Supplementary Table 1 and Table 2) [20]. The tested 
combinations were 12.5 µM SRg3 and 6.2 µM RRg3 (C1), 25 µM SRg3 and 12.5 µM 
RRg3 (C2), and 50 µM SRg3 and 25 µM RRg3 (C3). 
2.5. Transwell migration assay 
The experiment was performed as previously described [16]. A total of 1 × 105 of 
pre-treated MDA-MB-231 and HCC-1143 cells were collected in 250 μL of serum-free 
media containing vehicle control or Rg3 combinations. The cells were added to the 
upper chamber of Corning® transwell plates (8 µm pore size) with complete media in 
the lower chamber. The experiment was performed in triplicate and the results were 
represented as mean ± SD. 
2.6. Proliferation assay 
Crystal violet assay (CVA) was used to study the effect of Rg3 on the proliferation 
of TNBC cells, as previously described [16]. Briefly, MDA-MB-231, HCC1143 and 
MCF-12A cells were seeded at 5 × 103 cells/well of 96-well flat-bottom cell culture 
plates. After overnight incubation, the cells were exposed to the vehicle or Rg3 
combinations. On days 0 (drug exposure day), 1 and 3, cells were stained with crystal 
violet and the absorbance was measured at 595 nm using FLUOstar Optima microplate 
reader (BMG Labtech, Offenburg, Germany). Each treatment replicated 6 times and 
the data were shown as mean ± SD.  
2.7. Culture of mammospheres 
Mammospheres were grown in MammoCult™ Human Medium Kit (Stem Cell 
Technologies, Vancouver, Canada) as recommended by the manufacturer. The media 
was supplemented with MammoCult™ proliferation supplement, hydrocortisone and 
heparin at final concentrations of 10%, 0.5% and 0.2%, respectively. Briefly, the cells 
were harvested, washed and resuspended in complete MammoCult media at the 
density of 4 × 103 cell/cm2 in 6-well ultra-low attachment plates (Corning® Costar®). 
Following a 7-day period, mammospheres were collected in a tube, centrifuged at 350 
x g, 10 min, 4°C, and dissociated using 100 μL TrypLE™ Express (phenol red-free, 
Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and pipetting. Then, 1 mL of 
cold DPBS supplemented with 2% FBS was added to the cells. The cells were then 
centrifuged at 350 x g, 10 min, 4° C. Supernatant was then removed, and single cells 
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were suspended in MammoCult media, counted and seeded in 6-well ultra-low 
attachment plates exposed with vehicle or C3 for 3 days.  
2.8. Mammosphere formation efficiency (MFE) 
Mammospheres, exposed to vehicle or Rg3, were collected, counted, seeded in 24-
well ultra-low attachment plates at the density of 4000 cell/cm2. They were exposed to 
the vehicle or Rg3 for 4 days. Then, MFE was calculated as per the equation MFE (%) 
= number of mammospheres per well / number of seeded cells per well × 100, as 
previously described [23].  
2.9. Cell viability analysis 
Cells were grown and exposed to the drugs, as described in the previous 
paragraph. Single cells were prepared, and cell viability was measured using 
CellDrop™ FL Fluorescence Cell Counter (DeNOVIX). The experiment was performed 
in triplicate and the results are expressed as mean ± SD.  
2.10. Expression of stem cell markers 
Mammospheres were grown, treated with C3, collected and dissociated into single 
cells as before. Then the cells were washed in cold fluorescence-activated cell sorting 
buffer (FACS, 2% FBS, 0.05% sodium azide in DPBS), counted and 1 × 106 cell/mL FACS 
was prepared. The antibodies used to study the expression of CD44 and CD24 markers 
were as follows: APC mouse anti-human CD44 (BD Pharmingen™, BD Biosciences, 
CA, USA), APC mouse IgG2b, κ isotype control (BD Pharmingen™, BD Biosciences, 
CA, USA), PE mouse anti-human CD24 (BD Pharmingen™, BD Biosciences, CA, USA) 
and PE mouse IGg2a, κ isotype control (BD Pharmingen™, BD Biosciences, CA, USA). 
APC-Cy7 (100 µL per tube) was used to select for live cells. Incubation with antibodies 
or isotype controls was for 30 min in darkness at 4°C. Cells were washed twice in 1 mL 
FACS buffer and resuspended in 100 µL of FACS buffer. Expression of ALDH was 
studied using ALDEFLUOR™ Kit (Stem Cell Technologies), based on the 
manufacturer's protocol. An aliquot of 1 × 105 cells/tube was prepared on ice for 30 min 
staining with 20 µL antibody or isotype control. Prior to analysis, the cells were 
washed twice in 1 mL FACS buffer and resuspended in 100 µL of FACS buffer. The 
experiments were performed in triplicate and the results are expressed as mean ± SD.  
2.11. AKT pathway phosphorylation array 
A Human/Mouse AKT Pathway Phosphorylation Array C1 (RayBiotech, 
Norcross, GA, USA) was used to evaluate the effect of C3 on the signalling of AKT. 
This array measures the expression of 18 phosphorylated proteins in this signalling 
pathway. Mammospheres were grown from both TNBC cell lines, exposed to drugs 
and collected as described above. Mammospheres were washed twice in cold DPBS. 
Protein was extracted with a protein inhibitor cocktail and phosphatase inhibitors 
included as recommended by the manufacturer. Bio-Rad Protein Assay Dye Reagent 
Concentrate (Bio-Rad, Hercules, CA, USA) was used for the determination of protein 
levels. Image Lab™ Software (version 6.1) was used to measure the density of each 
dot. The results are shown as the mean ± SD of two replicates.  
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2.12. In silico molecular docking 
The interaction of Rg3 with four tyrosine kinase receptors was studied via 
molecular docking. The SMILES structure of Rg3 isomers, sorafenib, lenvatinib and 
rapamycin were obtained from PubChem. The crystal structure of epidermal growth 
factor receptor (EGFR) (3W33), human epidermal growth factor receptor-2 (HER-2) 
(3PP0), insulin-like growth factor-1 receptor (IGF-1R) (1JQH), and platelet derived 
growth factor receptor (PDGFR) (5GRN), the FKBP12 rapamycin-binding (FRB) 
(1FAP) and Ras homolog enriched in brain (Rheb) (6BSX) were obtained from the 
protein data bank of NCBI (RCSB PDB). The UCSF Chimera program (version 1.15-
mac64) and Autodock Vina algorithm (version 1.1.2_Mac) were used to make the 3D 
structure of Rg3, perform the molecular docking. The Gibbs free energy of protein-
ligand binding (kJ/mol) was predicted based on the flexible ligand docking simulations 
within the docking grids on defined interaction sites of each specific protein, as 
previously described [16]. 
2.13. Developing the mouse model of mTNBC 
Female Nod scid gamma (NSG) mice (6-8 weeks old) were purchased from Animal 
Resources Centre (Canning Vale, WA, Australia). Five days prior to commencement 
of the study, the mice were acclimatized to the animal housing facility, in pathogen-
free conditions. Throughout the study, the mice were weighed and checked on a daily 
basis for general well-being or any signs of toxicity. The experiments were performed 
according to the guidelines for the ethical use of animals in research and were 
approved by the Animal Ethics Committees of the University of Adelaide (M-2019-
068, 01/08/2019). To prepare MDA-MB-231-Luc cells for injection into mice, they were 
grown as mammospheres for 7 days. On the day of cell inoculation, the cells were 
collected, centrifuged at 350 x g, for 5 min at 4°C and washed twice in DPBS. The cells 
were counted and 1 × 106 cells (viability > 95%) were resuspended in 50 µL cold DPBS. 
A total of 100 µL of cells in a 1:1 ratio of Matrigel (Corning® Matrigel® Basement 
Membrane Matrix, Phenol red-free, LDEV-free)/DPBS were injected into the 4th right 
mammary fat pad (MFP), using aseptic technique. 
2.14. Drug administration and toxicity assessment 
Drugs were dissolved in DMSO and stored at -20°C as aliquots. Before injection to 
mice, an aliquot was thawed, mixed with 70% DPBS and 20% Cremophor EL® 
(Millipore Corp., Billerica, MA USA). The vehicle group received a combination of 10% 
DMSO, 20% Cremophor EL and 70% DPBS. Doses administered to mice were an 
extrapolation of in vitro results considering the total body water volume (10.35 mL) in 
a mouse of an average weight of 18 g. In the first study (study A) the mice received a 
combination of 50 µM SRg3 and 25 µM RRg3, equivalent to 23 and 11 mg/kg (combo 
A), respectively. Based on the encouraging results of this study, study B was designed 
in which the mice received a combination of 100 µM SRg3 and 50 µM RRg3, equivalent 
to 45 and 23 mg/kg (combo B), respectively. Drug administration started on day 12 in 
study A and day 5 in study B. Study A and B lasted for 40 and 23 days, respectively. 
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The drugs were injected subcutaneously three times a week. To assess the toxicity of 
the treatment, the mice were daily checked for any adverse changes including changes 
in body weight, changes in behaviour, fur condition, movement, posture, breathing 
and hydration level. 
2.15. IVIS imaging and tumour size measurement 
To non-invasively monitor the growth of the tumour and development of 
metastasis, the IVIS® Spectrum Imaging system (PerkinElmer, Boston, Massachusetts, 
USA) was used. The mice were anaesthetized and given a subcutaneous injection of 
100 µL of luciferin solution (Xenolight™ D-luciferin potassium salt, PerkinElmer) at 
150 mg/kg, 20 min before imaging. Mice were imaged once a week. Living Image® 
software (version 4.7.3; Perkin Elmer) was used to quantify the photons emitted from 
the mice as photons/sec/cm2. Furthermore, calliper measurement was used to measure 
the volume of the primary tumour using the equation: (shortest diameter of the 
tumour)2 × longest diameter of the tumour / 2. 
2.16. H&E staining and proliferative area measurement 
At the end of the experiment, the mice were humanely euthanized. Primary 
tumours and organs including lungs and lymph nodes were fixed in formalin neutral 
buffered, 10%, histological tissue fixative (Sigma-Aldrich) for 2 days, dehydrated and 
wax infiltrated (Excelsior AS™ Tissue Processor, Thermo Scientific™) and embedded 
in paraffin (HistoStar™ Embedding Workstation, Thermo Scientific™). Then, 4-µm 
thick tissue sections were prepared using a Microm HM 325 Microtome. Tissue slides 
were then stained for H&E, imaged using a NanoZoomer 2.0-HT slide scanner and 
viewed with NDP.view2 software (Hamamatsu Photonics, Shizuoka, Japan). The area 
of necrotic tissue relative to the whole cross-sectional area of the tumours was 
measured using ImageJ. 
2.17. Statistical analysis 
GraphPad Prism (version 9.0.0 for mac, GraphPad Software, San Diego, California 
USA, www.graphpad.com) was used to perform student's t-test, one- or two-way 
analysis of variance. The significance cut-off was considered to be p < 0.05. 
3. Results 
3.1. RSM for the effect of Rg3 on cell migration 
The RSM contour plot (Figure 1a) shows the regions of optimised concentrations 
of SRg3 and RRg3 for migration (%) in MDA-MB-231 cell line. Different regions with 
different colours in the contour plot show the predicted percentage of cell migration 
in response to the combination of SRg3 and RRg3. Figure 1b shows the 3D surface plot 
of the combination of SRg3 and RRg3 in this cell line. The optimum region in which 
minimum migration is achieved is shown with dashed line circles. Based on the RSM 
modelling, in this region, the concentration of the two drugs is optimised to achieve 
the maximum inhibition of migration. Previously, we showed that the combination of 
50 µM SRg3 and 25 µM RRg3 was the optimised combination for inhibition of loop 
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formation in HUVEC cells [20]. Based on this RSM, this combination gives 22.5% cell 
migration in MDA-MB-231 (Figure 1c). As shown in Figure 2a, the average cell 
migration achieved with C3 was about 15%, which falls into the predicted region in 
the RSM model.  
 
 
 Figure 1. The calculated (a) contour plot and (b) 3D surface plots (viewed 
from two angles) for cell migration based on the response surface 
methodology model developed to optimise and confirm the efficacy of SRg3 + 
RRg3 drugs in combination in MDA-MB-231 cell line. Dashed circles show the 
optimised minimal response area. (c) shows the predicted cell migration (%) 
with different combinations of SRg3 and RRg3. Results (%) is the percentage 
of expected migration. 
3.2. Rg3 inhibits migration but not proliferation in TNBC cell lines 
The effect of individual or combinations of Rg3 epimers on the migration of TNBC 
cells was tested in a circular scratch-wound (2D) and a transwell (3D) migration assay 
(Figure 2).  
After a three-day pre-treatment with individual or combinations of Rg3 epimers, 
MDA-MB-231, compared to HCC1143, showed more sensitivity to the anti-migratory 
effects of Rg3 only in the 2D assay. In MDA-MB-231, each of the three tested 
combinations, C3, C2 and C1, significantly inhibited cell migration to 15%, 38% and 
52% of vehicle control, respectively (Figure 2a). This was similar to the predicted RSM 
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model of <30%, 40-50% and 60-70% for C3, C2 and C1, respectively (Figure 1b). In 
HCC1143, 50 and 100 µM SRg3 inhibited cell migration by about 30% (p < 0.05) and 
among the combinations, only C3 significantly inhibited the 2D migration of cells (p < 
0.0001) (Figure 2a). These results also indicated that with C1 and C2 average cell 
migration was about 62% and 48%, respectively, which fall into the appropriate 
regions predicted by RSM (Figure 1b). These regions are 60-70% for C1 and 40-50% for 
C2, respectively (Figure 1b). C3 inhibited cell migration by about 85% and 92% in 
MDA-MB-231 and HCC1143 cell lines, respectively. 
 
Figure 2. Effects of SRg3, RRg3 and the combination of both on (a) circular 
scratch migration and (b) transwell migration assays on MDA-MB-231 and 
HCC1143. Datapoints show mean ± standard deviation (SD) of 6 (a) and 3 (b) 
replicates. (c) Anti-proliferative effect of C3 (50 µM SRg3 + 25 µM RRg3) on 
TNBC cell lines (MDA-MB-231 and HCC1143) and a normal breast cell line 
(MCF-12A). Each data point represents 6 replicates and shown as mean ± SD. 
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All comparisons are with the vehicle-treated cells, p < 0.05. * p < 0.05, ** p < 
0.01, *** p < 0.001 and **** p < 0.0001. 
The transwell assay showed that in both cell lines, single epimers significantly 
inhibited cell migration (p ≤ 0.0002) (Figure 2b). All three combinations in HCC1143 
and C2 and C3 in MDA-MB-231 showed efficacy in inhibition of 3D migration of cells 
(p < 0.0001). In MDA-MB-231, C3 showed the highest efficacy by almost completely 
inhibiting cell migration across the membrane (p < 0.0001). Figure 2c shows the anti-
proliferative effects of C3 on the TNBC cell lines and a normal breast epithelial cell 
line. As shown in this figure, this treatment did not inhibit the proliferation of these 
cell lines. 
3.3. Rg3 decreases MFE in TNBC 3D models, via decreasing ‘stemness’ of the cells 
The cells in the presence of vehicle formed mammospheres and in the presence of 
C3, mostly remained as single cells. MFE was significantly reduced in MDA-MB-231 
(p = 0.0003) and HCC1143 (p < 0.0001) (Figure 3a). Viability of both MDA-MB-231 and 
HCC1143 cells were not significantly decreased (Figure 3b). Flow cytometric analysis 
of apoptosis (Supplementary Figure 1a) and cell cycle (Supplementary Figure 1b) 
showed that there were no significant changes in the percentage of apoptotic cells or 
induction of cell cycle arrest.  
The expression of CD44/CD24 (Figure 3c and 3d) and ALDH (Figure 3e) was 
studied in both TNBC mammospheres. Cancer stem cells play important roles in 
driving initiation, progression, metastasis and recurrence and CD44, CD24 and ALDH 
are widely known breast cancer stem cell markers [6]. It was shown that a high ratio 
of cells expressing CD44 to CD24 was correlated with strong tumorigenicity of breast 
cancer and ALDH was correlated with the metastatic capacity of the tumour. These 
markers were correlated with breast cancer malignancy [6]. The CD44+/CD24-/low 
phenotype was also correlated with poorer prognosis in TNBC patients and together 
with ALDH+ are expressed in axillary lymph node (aLN) metastasis [6, 24]. MDA-MB-
231 and HCC1143 cell lines have mesenchymal and epithelial characteristics, 
respectively, which is also reflected in the expression of CD44+/CD24-/low phenotype in 
mammospheres. Figure 3c and 3d show that compared to HCC1143, MDA-MB-231 
had higher expression of CD44+/CD24- phenotype as mammospheres. Exposure to C3, 
decreased the expression of CD44+/CD24- phenotype in MDA-MB-231 mammospheres 
by 35% (p = 0.001) (Figure 3c). MDA-MB-231 showed a more significant decrease in 
the ratio of cells expressing CD44 to CD24 (p = 0.001); a double negative subpopulation 
was also observed (Figure 3c and 3d). 
Likewise, with HCC1143 mammospheres, upon exposure to C3, a double-negative 
subpopulation of cells was created and the ratio of cells expressing CD44 to CD24 was 
significantly decreased (p = 0.02) (Figure 3d). In both mammospheres, expression of 
CD44 was significantly decreased (Figure 3e). MDA-MB-231 cells express low levels 
of ALDH [25] and that expression was not altered by C3. Expression of ALDH in 
HCC1143 was only slightly decreased by C3 treatment (p < 0.05) (Figure 3e). Therefore, 
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decreased expression of CD44+ phenotype and decreased ratio of CD44 to CD24 might 
play a more important role in the anti-cancer effects of C3. 
 
 
Figure 3. (a) Mammosphere formation efficiency (MFE) and (b) viability of 
MDA-MB-231 and HCC1143 grown as mammospheres and exposed to C3 (50 
µM SRg3 + 25 µM RRg3). Expression of (c) CD44+/CD24- phenotype, (d) ratio 
of CD44 and CD24 expressing cells, (e) CD44+ expression and (e) expression of 
ALDH in mammospheres exposed to combination of SRg3 + RRg3. Each 
datapoint represents mean ± SD of three replicates. Statistical comparisons are 
between the treated and vehicle groups, p < 0.05.  
3.4. Effect of Rg3 on Akt/mTOR signalling 
Receptors tyrosine kinases (RTKs) such as EGFR and IGF-1R are overexpressed in 
TNBC, are considered to be prognostic and predictive markers [26-28], and are 
potential targets for treatment. Activation of RTKs triggers multiple signalling 
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pathways which guarantees cell cycle progression, proliferation, survival, migration 
and angiogenesis (Figure 4a). We had previously shown that Rg3 interacts with 
VEGFR2, in silico and in vitro, and functions as an allosteric modulator of the receptor 
[20]. In this study, we screened the interaction of Rg3 with some other RTKs.  
Table 1 shows the binding scores of Rg3 epimers with EGFR, HER-2, IGF-1R and 
PDGFR. The binding scores were compared with those of two known tyrosine kinase 
inhibitors (TKIs), sorafenib and lenvatinib.  
As shown in Table 1, both TKIs are predicted to have good binding scores with the 
receptors. With Rg3 epimers, the best scores belonged to the interaction of SRg3 and 
RRg3 with IGF-1R, being -8 and -7.5 kJ/mol, respectively. Figure 4b and 4c show the 
interaction of SRg3 and RRg3 with ATP-binding pocket of IGF-1R, respectively. As 
shown in these Figures, Rg3 molecules are predicted to be well placed in the ATP-
binding pocket of the receptor.  
Table 1. Binding score (kJ/mol) between Rg3 epimers and tyrosine kinase 
receptors, FRB site of mTOR or Rheb, and the number of hydrogen bonds (H-
bonds) predicted by Chimera program and Autodock vina algorithm. 
 Binding score (kJ/mol) (number of H-bonds) 
Molecule EGFR HER-2 IGF-1R PDGFR FRB Rheb 
SRg3 -6.9 (2) 2.7 (0) -8.0 (2) -2.8 (1) -7.0 (1) -8.0 (3) 
RRg3 -6.9 (2) 2.7 (1) -7.5 (0) -2.8 (1) -7.2 (1) -8.0 (4) 
Sorafenib -9.6 (0) -10.8 (1) -8.9 (1) -11.2 (1) n.d.* n.d. 
Lenvatinib -10.4 (1) -9.6 (1) -7.9 (1) -10.1 (1) n.d. n.d. 
Rapamycin n.d. n.d. n.d. n.d. -7.6 (0) n.d. 
* not determined 
Following activation of a RTK, different downstream signalling pathways might 
be activated. PI3K/AKT and Ras/Raf/MEK/ERK are two such pathways which are in 
crosstalk. PI3K phosphorylates and activates AKT. AKT has several targets, the action 
of which leads to cell survival, migration, proliferation and angiogenesis. One of the 
important targets of AKT is mammalian target of rapamycin complex 1 (mTORC1), 
which is sensitive to and regulated by several signals including nutrients and growth 
factors [29].  
Two key substrates of mTORC1 are eukaryotic translation initiation factor 4E 
(eIF4E)-binding protein 1 (4E-BP1) and P70 ribosomal protein S6 kinase (P70S6K). 
They are crucial factors in translation initiation that predominantly mediate the 
translational functions of mTORC1. mTORC1, via phosphorylation of 4E-BP1, 
inactivates this protein, releasing p-4E-BP1 from eIF-4E. Activated eIF-4E, then 
initiates translation (Figure 4a). mTORC1 also phosphorylates and activates P70S6K. 
Activated P70S6K phosphorylates and activates ribosomal protein S6 (RPS6), a 
component of S40 ribosomal subunit, which plays an important role in global 
translation and cell growth and glucose homeostasis (Figure 4a) [30]. The effect of C3 
on the phosphorylation of proteins downstream of the activation of AKT on two TNBC 
mammosphere models is shown in Figure 4d-e. Mammospheres, originated from two 
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different TNBC cell lines with mesenchymal (MDA-MB-231) or epithelial (HCC1143) 
characteristics reacted differently to C3.  
In MDA-MB-231, the expression of phosphorylated forms of 4E-BP1 (p < 0.0001), 
RPS6 (p = 0.0001), P70S6K (p = 0.0032) and phosphatase and tensin homolog (PTEN) 
(p = 0.0109) were significantly decreased (Figure 4d). PTEN is a tumour suppressor 
gene, an inhibitor of the activation of PI3K and its subsequent signalling (Figure 4a). 
In this study, phosphorylation of Ser380, which inactivates PTEN was measured. It 
was shown that C3 significantly decreased the levels of inactive phosphorylated PTEN 
(p = 0.0109), which would improve the tumour suppressor function. In MDA-MB-231, 
C3 also reduced mTOR-initiated ribosomal translation via decreased phosphorylation 
of 4E-BP1, P70S6K and RPS6.  
 
Figure 4. (a) An Illustration of signalling of PI3K/AKT/mTOR and 
Ras/Raf/MEK/ERK signalling pathways. Dashed black arrows show where 
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Rg3 is affecting and affected proteins are shown in blue. Interaction of (b) SRg3 
and (c) RRg3 with ATP-binding pocket of IGF-1R. The effects of C3 (50 µM 
SRg3 + 25 µM RRg3) on the expression of phosphorylated proteins 
downstream of activation of AKT signalling in (d) MDA-MB-231 and (e) 
HCC1143 cell lines. The data show mean ± SD of two replicates. Statistical 
comparisons are between the treated and vehicle groups, p < 0.05, (f) FKBP12 
rapamycin-binding site of mTOR binding to SRg3 and RRg3 and (g) Rheb 
protein binding to SRg3 and RRg3. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** 
p < 0.0001. 
Similar to MDA-MB-231, C3 treatment of HCC1143 mammospheres reduced the 
levels of the phosphorylated forms of PTEN (p < 0.0001) and RPS6 (p < 0.0001). In 
addition, the expression of phosphorylated forms of proline-rich AKT substrate of 
40 kDa (PRAS40) (p < 0.0001), Raf-1 (p < 0.0001), and ribosomal S6 kinase (RSK1) (p = 
0.0038) were also decreased (Figure 4e). PRAS40 is a substrate of AKT and a 
component and substrate of mTORC1 (Figure 4a). AKT mediated phosphorylation of 
PRAS40 at Thr246, studied in this assay, inactivates PRAS40 in a way that mTORC1 
restores its function [29]. Hence, decreased phosphorylation of PRAS40 decreases the 
activation of mTORC1.  
RSK1 is a member of the family of 90 kDa RSKs. RSKs are activated downstream 
of activation of Ras/Raf/MEK/ERK pathway. The signalling of Ras/Raf/MEK/ERK 
plays roles in cell proliferation, survival, migration and angiogenesis. It is in 
interaction with the signalling of the AKT pathway. Upon activation, RSKs play roles 
in regulating several cellular functions including cell proliferation, survival and 
motility [31], via interaction with phosphorylation of 4E-BP1 and RPS6 [32]. Raf-1 is a 
proto-oncogene and a serine/threonine protein kinase that is activated downstream of 
activation of Ras, leading to activation of MEK and ERK. Phosphorylation at SER-301 
of Raf-1, studied in this assay, is a result of ERK-mediated feedback phosphorylation 
of Raf-1 [33].  
Considering the changes in the phosphorylation of proteins downstream of 
activation of mTOR, we performed molecular docking to find out if Rg3 epimers have 
any good binding with mTORC1. In this preliminary screening, we tested two sites of 
the complex, the FRB and Rheb. The FRB site is one of the functional domains of mTOR 
kinase, where rapamycin binds. At this site, SRg3 and RRg3 have binding score of -7 
and -7.2 kJ/mol, respectively, which are comparable to the binding score of rapamycin, 
-7.6 kJ/mol (Table 1). Furthermore, SRg3 and RRg3 had binding scores of -8.0 kJ/mol 
with Rheb. Rheb is a GTP-binding protein that upon insulin and growth factor 
stimulation, binds to and activates mTORC1. Molecular docking showed that Rg3 has 
a good binding score with Rheb and hence, could decrease the signalling of mTOR 
axis, the inhibition of which is important in cancer treatment [34, 35]. 
3.5. In vivo evaluation of the efficacy of Rg3 combo 
To evaluate the in vivo efficacy of C3 two in vivo studies were conducted. With 
combo A (23 mg/kg SRg3 + 11.5 mg/kg RRg3) weekly IVIS imaging demonstrated that 
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the treatment significantly decreased the growth rate of the primary tumour (p = 
0.0004) (Figure 5a). This result was confirmed with calliper measurements (Figure 5b). 
This treatment also significantly decreased the total body tumour burden (p < 0.0001) 
(Figure 5c) and thoracic tumour load (p = 0.0066) (Figure 5d). Lung metastases were 
confirmed with ex vivo imaging (Figure 5e) and H&E staining (Figure 5f).  
Treatment with C3 significantly reduced the number of metastatic aLNs (Figure 
5g). Five of 8 mice in the vehicle group showed an enlarged contralateral (left) aLN, 
whilst only one mouse in the treatment group had an affected left aLN. Mice in both 
groups had an enlarged ipsilateral (right) aLNs. Ex vivo imaging (Figure 5h) and H&E 
staining (Figure 5i) confirmed the presence of tumour in the metastatic aLNs. 
 
Figure 5. Outcomes of administration of combo A and B to a metastatic model 
of TNBC in NSG mice. Administration of combo A (a) decreased the rate of 
primary tumour growth measured with IVIS spectra, (b) primary tumour 
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volume measured with a calliper, (c) body burden of the tumour, (d) the load 
of metastasis in the thorax and (g) number of enlarged left axillary lymph 
nodes, indicated with white arrows. (e) and (h) show representative ex vivo 
IVIS images of lung and lymph nodes and (f) and (i) are the results of histology 
on lung and lymph node, respectively, showing tumour cells in the tissues. 
Black arrows show the region in the tissue that is magnified. The scale bar 
shows 25 µm. Administration of combo B to mice, (j) decreased, though not 
significantly, the average body burden of the tumour, (k) primary tumour 
volume measured with a calliper in situ, or (l) ex vivo. (m) The treatment also 
significantly decreased the load of tumour in the lungs of mice, (n) there were 
no significant differences between the groups in terms of necrotic or viable 
area, black arrow shows the necrotic area and dashed arrow shows the 
proliferative region and the scale bar shown 2.5 mm. Each treatment group 
included 8 mice. All IVIS scales show count values between 600-60000. The 
data are presented in (a-c), (j-n) are mean ± SD with p < 0.05. * p < 0.05, ** p < 
0.01, *** p < 0.001 and **** p < 0.0001. 
Next, we doubled the doses to 46 mg/kg SRg3 and 23 mg/kg RRg3 (combo B). 
Administration of a higher dose of Rg3 to mice caused a lessening trend in the average 
total flux of the whole body (Figure 5j), which started as early as the second dose. 
However, this decrease in total body flux was not statistically significant. The escalated 
dose also significantly decreased the size of the primary tumour. A significant 
difference between the treatment and the vehicle group was noticed as early as day 14 
(p = 0.01). Tumour volume measurements on days 16 (p = 0.01), 18 (p = 0.0056), 21 (p < 
0.0001) and 23 (p < 0.0001) confirmed the decreased size in the treatment group (Figure 
5k). 
Ex vivo measurement confirmed the treatment significantly decreased the primary 
tumour volume (p = 0.0002) (Figure 5l). Ex vivo imaging of the excised lungs also 
showed a significant decrease in the bioluminescence photons detected in the 
treatment group lungs (p = 0.0197) (Figure 5m). Furthermore, there were no significant 
differences between the groups in terms of necrotic or proliferative areas (Figure 5n). 
In these two studies, no signs or symptoms of drug toxicity were observed. There were 
no significant differences between the two groups in terms of weight loss, fur 
condition, posture and behaviour (Supplementary Figure 3). 
4. Discussion 
The objective of this research was to study and introduce a plausible treatment 
option for TNBC and mTNBC. In our previous studies, we showed that epimers of Rg3 
have stereoselective activities [16] and then using an RSM model, the combination of 
these two epimers was optimised for its anti-angiogenic effects, in vitro [20]. In the 
current study, first, the validity of the optimised combination was tested in MDA-MB-
231 and it was shown that the combination (C3) exerted a high anti-migration effect in 
the circular scratch migration assay. The validity of the RSM model was also tested 
with two other combinations (C1 and C2). In both migration assays, C3 showed high 
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efficacy in inhibiting cell migration of both TNBC cell lines, while it had no anti-
proliferative effect on them. Then the efficacy of C3 was tested in mammospheres, 
which better mimic the in vivo drug responses of human breast tumour. Formation of 
mammosphere is related to ‘stemness’ of the cancer cells [36]. The treatment 
significantly inhibited MFE. As tested in this study, one contributing reason for the 
decreased MFE could be the decreased ‘stemness’ of the cells.  
In this study, combined expression of CD44 and CD24 were studied. CD44 and 
CD24 are markers that are more expressed on progenitor-like cells and more 
differentiated cells, respectively. In breast cancer cells with CD44+ phenotype, genes 
that are involved in cell motility and angiogenesis were highly expressed, the cells 
were more mesenchymal, motile, and predominately estrogen receptor negative. In 
breast cancer patients, CD44+/CD24- phenotype related to triple negativity and 
unfavourable prognosis [37] worse clinical behaviour [38] and distant metastasis [39]. 
These cells expressed higher levels of pro-invasive genes and had highly invasive 
properties [40]. Studies also showed that downregulation of CD44 reduced 
doxorubicin resistance of CD44+/CD24- breast cancer cells [41]. It was previously 
shown that 50 µM SRg3 decreased the CD44+/CD24- subpopulation in MDA-MB-231 
[42]. In our study, RRg3 was added as a co-treatment and the combination caused a 
double negative subpopulation of cells. In addition, it was previously reported that 
Rg3 inhibited EMT via inactivating P38 MAPK and Smad2, increased expression of E-
cadherin and Snail and decreased expression of vimentin (reviewed in [14]). Decreased 
expression of CD44 might be another contributing factor to this phenomenon, because 
CD44 also plays roles in EMT [43]. 
The mechanism by which expression of these stem cell markers is decreased in 
these cells might be via inhibition of PI3K/AKT pathway. It has been shown that 
inhibitors of this signalling pathway, such as quercetin [44] decreased 
CD44+/CD24- phenotype and hence breast cancer ‘stemness’. Previously, Rg3 was 
shown to affect the PI3K/AKT signalling and decreased the activation of Akt, mTOR, 
GSK-3β, 4E-BP1, Src, and P70S6K (reviewed in [14]). In the present study, it was shown 
that C3 affects AKT/mTOR signalling in both TNBC cell lines tested. Rg3 also was 
predicted to have a good binding score with IGF-1R and could be a blocker of mTOR 
activation via blocking the interaction site of Rheb with mTOR. mTOR regulates 
several cellular functions including cell adhesion, changes in extracellular matrix and 
migration [45]. C3 may have exerted its anti-cancer actions by affecting the regulatory 
function of mTOR.  
We previously showed that in endothelial cells, C3 was an inhibitor of AKT 
signalling, with the highest efficacy on p-mTOR and its substrates, p-4E-BP1 and p-
P70S6K. Consistent with those results, in MDA-MB-231, both of these proteins were 
affected. 4E-BP1 plays a role in the mTOR-initiated translation of factors involved in 
metastasis such as matrix metalloproteinase-9, fibroblast growth factor, vascular 
endothelial growth factor, C-MYC and cyclin D1 [45]. Along with these roles, 4E-BP1 
was introduced as an oncogene in breast cancer [46], playing a role in the proliferation 
of breast cancer cells [47]. Furthermore, mTORC1/4E-BP1 regulated neural stem cell 
renewal capacity [48], a pathway which also might play a role in stem cell renewal in 
breast cancer and needs further investigation.  
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p-P70S6K plays roles in cell growth and cell cycle progression and is also identified 
as an important factor in breast cancer survival and predicting response to treatment 
[49]. This protein may also play roles in metastasis as overexpression of p-P70S6K was 
linked to metastasis in gastric carcinoma [50]. It is also responsible for the 
phosphorylation of protein S6. RPS6 is involved in the regulation of cell size and 
glucose homeostasis [30]. Hyperphosphorylation of this protein via 
AKT/mTOR/p70S6K pathway was relevant to the progression of non-small cell lung 
carcinoma (NSCLC) [51]. In both of our tested cell lines, the levels of p-RPS6 were 
significantly reduced, which might indicate the importance of this protein in the Rg3-
induced effects observed in both cell lines and potential of involvement of IGF-1R and 
glucose metabolism. The role of Rg3 with IGF-1 was previously studied and it was 
shown that Rg3 decreased the expression of IGF-1 causing a reduced cell proliferation 
in multiple myeloma and breast tumours (reviewed in [14]). This could further 
highlight the role of Rg3 in IGF-1R signalling. 
p-PRAS40 is an important component and regulator of mTORC1. The expression 
of p-PRAS40 has been reported to be prognostic in gastric cancer [52]and prostate 
cancer [53] patients. Raf-1 and RSK1 are activated downstream of activation of 
Ras/Raf/MEK/ERK pathway. RSKs, via enhancing proliferation, migration and 
invasion, have multiple roles in breast cancer [54]. RSK inhibitors were developed to 
bypass the side effects of MEK inhibitors, as RSKs have fewer but important targets 
which play roles in metastasis. The fact that 85% of these patients have activated RSKs 
makes them a good therapeutic target in TNBC [55]. 
In addition, the leading edge of migrating cells has a crucial role in cell migration 
and is a centre for local translation of required proteins for cell migration [56] for which 
mTOR plays a central role [57]. AQP1 together with other proteins important in cell 
migration such as focal adhesion kinase (FAK), work in complex at the leading edge 
to facilitate cell migration. Our preliminary testing has shown that C3 caused 
decreased activation of FAK and minor decreased expression of AQP1 in MDA-MB-
231 and HCC1143 mammospheres (Supplementary Figure 2). A decreased level of 
AQP1 expression was previously noted in endothelial cells exposed to C3 [20]. 
The efficacy of C3 was also evaluated in an mTNBC mouse model. Previously 
some studies reported the efficacy of Rg3 in mice breast cancer models (reviewed in 
[14]). In these studies, orally administered Rg3 promoted the anti-cancer effects of 
paclitaxel and capecitabine, and improved mice survival (reviewed in [14]). Although 
many studies suggested anti-migration mechanisms for Rg3 epimers and anti-
metastatic efficacy of Rg3 was shown in melanoma and colon cancer models (reviewed 
in [14]), until now, no studies have investigated the efficacy of Rg3 on an mTNBC 
mouse model. For the first time, we have evaluated the efficacy of Rg3 combination in 
a highly aggressive orthotopic mouse model of mTNBC. Furthermore, we changed the 
route of administration from oral to subcutaneous injection, hence, bypassing the 
gastrointestinal metabolism, first-pass effect and low bioavailability of Rg3 (reviewed 
in [14]). The primary and the increased dosing both showed efficacy in this mouse 
model. Reduction in tumour size was more meaningful with the escalated dosing, 
however, the percentage of necrotic tissue between the two groups was not 
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significantly different. Mollard et al. (2016), in a simulation study, showed that in this 
mTNBC mouse model, necrotic tissue had an almost constant ratio against total tissue 
volume [58]. Consistent with that, combo B did not change the ratio between necrotic 
and proliferative tissues in the vehicle or treated groups, however, primary tumour 
shrinkage was observed. This could mean that the treatment reduced the rate of 
proliferation in the primary tumour, which caused tumour shrinkage. Previously, we 
showed that at 100 µM SRg3, the proliferation of MDA-MB-231 was inhibited [16]. 
Furthermore, epimers of ginsenoside Rh2 and protopanaxadiol were suggested as 
potential active metabolites of Rg3, detected after intravenous injection to rats 
(reviewed in [14]), and these molecules have shown anticancer effects in MDA-MB-
231 [59, 60]. Therefore, the effects observed in this study might be a result of the 
combination of Rg3 and its metabolites. Further studies are required to investigate it. 
For the first time, we reported the anti-metastatic efficacy of combination Rg3 epimers 
in an mTNBC mouse model. Reduced metastatic load observed in this study is very 
impressive. Whether this treatment targets angiogenesis in vivo requires further 
investigation. Furthermore, the treatment was tolerable in mice and no signs of toxicity 
were observed. Single epimers administered to human have not shown toxicities 
(reviewed in [14, 20]) and therefore, it is not expected that the tested combination be 
any more toxic.  
5. Conclusions 
In conclusion, the optimised combination of SRg3 + RRg3 showed efficacy in 
inhibition of migration of TNBC cell lines, inhibited the MFE, reduced the ‘stemness’ 
of these cells and inhibited phosphorylation of proteins downstream of AKT/mTOR 
signalling. In silico studies suggest that Rg3 might be a potential mTORC1 inhibitor. 
Furthermore, in an mTNBC mouse model, the treatment shrunk the primary tumour 
and reduced the load of metastasis in mice, which introduces this drug as a potential 
treatment for TNBC. 
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Appendix A. Supplementary data 
The central composite design technique (CCD) was employed with three levels; 
low, mid, and high values corresponding to -1, 0 and +1 for input parameters which 
are concentration of SRg3 and RRg3. In the present study, the concentration ranged 
from (0-100 µM) for SRg3 and (0-50 µM) for RRg3 were selected. Supplementary Table 
1 represents the values corresponding to low, mid, and high bounds of concentrations 
for Rg3 epimers. 
Supplementary Table 1. Low, mid and high values used for RSM model. 
Parameter Index 
Concentration (µM) 
Lowest value (-1) Centre Value (0) Highest Value (+1) 
SRg3 A 0 50 100 
RRg3 B 0  25 50 
 
Supplementary Table 2 represents the designed matrix used in the RSM analysis 
and the response (percent of cell migration). To optimize the combination of 
concentrations, the RSM model has reduced the total experiments to 13 iterations, with 
cell migration being the “main measurable target parameter”.  
Supplementary Table 2. Design Matrix developed for the RSM model. 






1 -1 -1 0 0 79.23 
2 0 0 50 25 18.40 
3 0 0 50 25 14.19 
4 0 0 50 25 15.55 
5 1 0 100 25 57.24 
6 0 0 50 25 12.09 
7 -1 1 0 50 64.33 
8 -1 0 0 25 79.23 
9 0 -1 50 0 72.40 
10 1 1 100 50 53.45 
11 0 1 50 50 63.92 
12 0 0 50 25 16.14 





Supplementary Figure 1. MDA-MB-231 cells were grown as mammospheres 
and exposed to C3 (50 µM SRg3 + 25 µM RRg3). (a) shows induction of 
apoptosis and (b) shows cell cycle arrest in these mammospheres exposed to 
vehicle or drug. The experiment was performed in triplicate and results are 
shown as mean ± SD.  
Apoptosis This assay was performed on mammospheres using Annexin-V-
FLUOS staining kit (Roche Diagnostics, Mannheim, Germany) as previously 
described [61]. Changes in the cell cycle of cells grown as mammospheres were 
studied using propidium iodide staining and BD FACSCanto™ II analysis, as 
previously described [62]. The experiment was performed using the BD 
FACSCanto™ II (BD Biosciences, San Jose, CA, USA) and FlowJo software, v 
10.4 (FlowJo, LLC, Ashland, OR, USA).  
 
Supplementary Figure 2. (a) Expression of AQP1 transcripts in MDA-MB-231 
and HCC1143 cells grown as monolayer or mammospheres. The experiment 
was performed in duplicate and the results are presented as mean ± SD. 
PureLink RNA mini kit (Life Technologies, Grand Island, NY, USA) was used 
to extract RNA and 20 ng RNA was used for reverse transcription using iScript 
cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA). The duplex 
TaqMan Gene Expression Assays for aquaporin-1 (AQP1; Hs01028916_m1; 
Applied Biosystems, Foster City, CA, USA) and the reference genes were 
CCSER2 (HS00982799_mH, Applied Biosystems, Foster City, CA, USA). 
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Protein expression of (b) AQP1 and (c) activation of FAK in MDA-MB-231 and 
HCC1143 mammospheres exposed to vehicle control (V) or C3 (50 µM SRg3 + 
25 µM RRg3). Total cell lysates were prepared and quantified. The 
experiments were repeated 2 times with 20 or 50 µg proteins. The antibodies 
used for immunostaining include anti-AQP1 antibody [EPR20325] (ab219055, 
Abcam, Cambridge, UK, 1:1000), anti-FAK antibody [EP6954] (ab40794, 
Abcam, Cambridge, UK, 1:1000), anti-phospho FAK antibody [EP2]60Y] 
phosphor Y397 (ab 81298, Abcam, Cambridge, UK, 1:1000). Goat anti-rabbit 
IgG H&L (HRP) (ab6721, Abcam, Cambridge, UK, 1:3000) was used as the 
secondary antibody.  
 
Supplementary Figure 3. Weight pattern of mice in the vehicle- or Rg3-treated 
groups in study A and B. There were no significant differences between the 
groups in terms of changes in body weight. 
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Chapter 5 Efficacy of the metabolites of ginsenoside Rg3 
5.1. Background 
As reviewed in chapter 1, a fundamental challenge with the administration of Rg3, 
which is more evident in oral administration, is its extensive metabolism. In fact, Rg3 
could be considered as not only a drug, but also a prodrug. The major active 
metabolites of Rg3 are deglycosylated epimers of ginsenoside Rh2 (S-Rh2 and R-Rh2) 
and protopanaxadiol (S-PPD and R-PPD). In this chapter, the efficacy of these 
molecules in inhibition of proliferation of a TNBC cell line and a human endothelial 
cell were studied. The mode of cell death in both cell types and the possibility of two 
programmed cell death types, apoptosis and necroptosis, was investigated using live 
cell imaging and discussed.  
Furthermore, the effect of epimers on loop formation and their potential anti-
angiogenic effects is discussed. The interaction of the epimers with VEGFR2 was 
studied using in silico molecular docking and in vitro studies. In silico molecular 
docking was also used to screen for the interaction of these molecules with AQPs to 
see whether these molecules have the potential to block AQP water transport.  
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5.3. Differential anticancer activities of the active metabolites of ginsenoside Rg3 
Article 
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Abstract 
Epimers of ginsenoside Rg3 (Rg3) have low bioavailability and are prone to 
deglycosylation, which produces epimers of ginsenoside Rh2 (S-Rh2 and R-Rh2) and 
protopanaxadiol (S-PPD and R-PPD). This study aimed to compare the efficacy and 
potency of these molecules as anti-cancer agents. Crystal violet staining was used to 
study the anti-proliferatory action of the molecules on MDA-MB-231 and HUVEC 
cells and compare their potency. Cell death and cell cycle were studied using flow 
cytometry and the mode of cell death was studied using live cell imaging. Anti-
angiogenic effects of the drug were studied using loop formation assay. Molecular 
docking showed the interaction of these molecules with vascular endothelial growth 
factor receptor-2 (VEGFR2) and aquaporin (AQP) water channels. VEGF bioassay 
was used to study the interaction of Rh2 with VEGFR2, in vitro. HUVEC was the more 
sensitive cell line to the anti-proliferative effects of S-Rh2, S-PPD and R-PPD. The 
molecules induced necroptosis/necrosis in MDA-MB-231 and apoptosis in HUVEC. 
S-Rh2 was the most potent inhibitor of loop formation. In silico molecular docking 
predicted a good binding score between Rh2 or PPD and the ATP-binding pocket of 
VEGFR2. VEGF bioassay showed that Rh2 was an allosteric modulator of VEGFR2. 
In addition, SRh2 and PPD had good binding scores with AQP1 and AQP5, both of 
which play roles in cell migration and proliferation. The combination of these 
molecules might be responsible for the anti-cancer effects observed by Rg3. 
Keywords: Ginsenoside Rg3, Ginsenoside Rh2, Protopanaxadiol, Epimer, Triple 
negative breast cancer, Angiogenesis 
 
1. Introduction 
Ginsenoside Rg3 (Rg3) is one of the best studied members of the ginsenoside 
family of molecules extracted from Panax ginseng. Like other ginsenosides, Rg3 has 
two epimers; 20(S)-ginsenoside Rg3 (SRg3) and 20(R)-ginsenoside Rg3 (RRg3). Several 
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studies have reported the anticancer properties of epimers of Rg3 (reviewed in [1, 2]). 
Orally administered Rg3 is a registered drug in China [3] and has been evaluated as a 
single drug in clinical trials in lung [4] and liver cancer patients [5] or in combination 
with other chemotherapies [3, 6]. However, several in vitro and in vitro animal studies 
have suggested an extensive metabolism of Rg3 in the gastrointestinal tract (reviewed 
in [1]). For example, low bioavailability of less than 3% was reported in Sprague–
Dawley rats [7]. Furthermore, after oral administration of 3.2 mg/kg of Rg3 [8] and 
RRg3 [9] in healthy people, tmax (time required to reach the maximum plasma 
concentration) was about 40 minutes and Cmax was about 16 and 1 ng/mL, respectively. 
These data suggested that metabolites of Rg3 could contribute to the oral efficacy of 
Rg3. While deglycosylation and oxygenation are reported as two major metabolic 
pathways of Rg3, deglycosylation is a more important pathway as it leads to the 
formation of the active metabolites ginsenoside Rh2 (Rh2) and protopanaxadiol (PPD) 
(Figure 1). Peng et al. (2016) showed that after oral or intravenous administration of 
SRg3 and RRg3, the respective deglycosylated epimers are detected in rats' plasma, 
namely 20(S)-ginsenoside Rh2 (S-Rh2), 20(R)-ginsenoside Rh2 (R-Rh2), 20(S)-
protopanaxadiol (S-PPD) and 20(R)-protopanaxadiol (R-PPD) (Figure 1) [10].  
 
Figure 1. The structure of epimers of ginsenoside Rg3 and their metabolites. 
Deglycosylation of 20(S)- and 20(R)-ginsenoside Rg3 produces 20(S)- and 
20(R)-ginsenoside Rh2 and 20(S)- and 20(R)-protopanaxadiol. The stereocenter 
on C20 is highlighted with a red colour and heteroatoms of the sugar molecules 
are shown in green. 
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Our group has been interested in finding novel treatments for metastatic triple-
negative breast cancer patients. We have shown the stereoselective activities of SRg3 
and RRg3 in inhibition of the proliferation, migration and invasion of triple negative 
breast cancer cell lines [11]. Aquaporins (AQPs) have been shown to play roles in cell 
proliferation, migration, invasion and angiogenesis (reviewed in [2, 12]). AQP1, AQP4 
and AQP5 localize at the leading edge of migrating cells and facilitate cell migration. 
Using molecular docking, we showed that Rg3 blocks AQP1 water channel with a 
good binding score (-9.4 kJ/mol), and in vitro, using oocyte swelling assay we showed 
that only SRg3, stereoselectively, blocked the water transport function of AQP1 [11].  
Continuing with the screening of ginsenosides as potential treatment options for 
metastatic triple-negative breast cancer, given the in vivo efficacy of Rg3 in lung and 
liver cancer, the aim of the current research was to investigate the anticancer properties 
of epimers of Rh2 and PPD, as potentially active metabolites of Rg3, which could 
contribute to the effects observed by this drug.  
2. Materials and Methods  
2.1. Cell lines, reagents and cell culture 
MDA-MB-231 was purchased from American Type Culture Collection (ATCC; 
Manassas, VA, USA) and grown in Dulbecco’s modified Eagle’s medium (DMEM; Life 
Technologies, Carlsbad, CA, USA) supplemented with 10% foetal bovine serum (FBS) 
(Corning, NY, USA) and 1% penicillin-streptomycin (pen strep; Life Technologies, 
Carlsbad, CA, USA). Human umbilical vein endothelial cells (HUVECs) and its media, 
EBM-2 Endothelial Cell Growth Medium-2 were both from Lonza (Lonza, Basel, 
Switzerland). 20(S)- and 20(R)- epimers of ginsenoside Rh2 and protopanaxadiol were 
from ChemFaces Biochemical Co. (Wuhan, China). Drugs were dissolved in dimethyl 
sulfoxide (DMSO D2650, HYBRI-MAX, Sigma-Aldrich, St Louis, MO, USA). Stocks of 
50 mM of the molecules was prepared and 25 mM aliquots were kept at -20°C to avoid 
freeze-thawing cycles. Concentrations of 0-100 µM of ginsenosides were used with 
maximum of 0.2% DMSO as the vehicle control. Cell lines were mycoplasma-free, as 
determined using the MycoAlert Detection Kit (Lonza) and/or a custom PCR-based 
assay, as described previously [13, 14]. 
2.2. Proliferation Assay 
To test the efficacy of the ginsenosides on cell proliferation, crystal violet assay 
(CVA) was used, as previously described [11]. Briefly, MDA-MB-231 and HUVEC cells 
were seeded at 3 × 103 and 0.8 × 103 cells/well of 96-well plates. On days 0, 1 and 3, CVA 
was performed and the absorbance of each well was read using FLUOstar Optima 
microplate reader (BMG Labtech, Offenburg, Germany) at 595 nm. The experiment 
included 6 replicates and the data are shown as mean ± standard deviation (SD). 
2.3. Cell viability and half-maximal inhibitory concentration (IC50) calculation 
Based on CVA data on day 3, cell viability and dose-response curves were plotted 
using non-linear regression using log(inhibitor) vs. normalized response using 
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GraphPad Prism (version 9.0.0 for Mac, GraphPad Software, San Diego, California 
USA, www.graphpad.com) to calculate IC50.  
2.4. Loop formation assay 
As previously described [15], 10 µL of Matrigel® (Corning® Matrigel® Basement 
Membrane Matrix, LDEV-free, cat# 354234, NY, USA) was used to coat each well of an 
Angiogenesis 96 Well µ-Plate (Ibidi, Martinsried, Germany). HUVEC was seeded at 
1.5 × 104 cells/well and exposed to the vehicle or 1, 10, 50 and 100 µM of ginsenosides. 
The number of formed loops in each well was counted after 8 h. The experiment was 
performed in triplicate. The data are presented as mean ± SD. 
2.5. Flow cytometric analysis of cell death 
The assay was performed as previously described [11, 16]. Briefly, MDA-MB-231 
and HUVEC cells were seeded at 1 × 105 and 0.5 × 105 cells/well of six-well plates and 
incubated overnight and then exposed with the drugs or vehicle for 3 days. Cells were 
harvested, stained using Annexin-V-FLUOS Staining Kit (Roche Diagnostics, 
Mannheim, Germany) and analysed using a BD FACSCanto II (BD Biosciences, San 
Jose, CA, USA), capturing 10,000 single-cell events per sample. Data were analysed 
using FlowJo software v10.4.0 (FlowJo, LLC, Ashland, OR, USA). The experiment was 
performed in triplicate and the data are presented as mean ± SD. 
2.6. Flow cytometric analysis of cell cycle 
The assay was performed as previously described [11, 16]. Briefly, MDA-MB-231 
and HUVEC cells were seeded at 1 × 105 and 0.5 × 105 cells/well of six-well plates and 
incubated overnight. Cells were exposed to the drugs or vehicle. After a 3-day 
exposure, the cells were harvested, washed twice and resuspended ice-cold Dulbecco’s 
phosphate buffered saline (DPBS, Gibco, Thermo Fisher Scientific, Waltham, MA, 
USA) with drop-wise addition of an equal volume of 100% ice-cold ethanol. The cells 
were fixed at -20°C for 2 h, washed and resuspended in 100 µL of propidium iodide 
(PI) staining solution consisting of 25 µg/mL PI (Sigma-Aldrich, St Louis, MO, USA), 
40 µg/mL bovine pancreas ribonuclease A (Sigma-Aldrich), and 0.25% Triton X-100 
(Sigma-Aldrich) in DPBS. The stained cells were analysed with a BD FACSCanto II, 
capturing 10,000 single-cell events per sample. Data were analysed using FlowJo. The 
experiment was performed in triplicate and the data are presented as mean ± SD. The 
sub-G1 population was considered as cell death. To calculate cell cycle arrest in each 
phase, the sub-G1 population was excluded. 
2.7. Studying mode of cell death using IncuCyte 
MDA-MB-231 and HUVEC cells were seeded at 6.6 × 103 and 1.5 × 103 cells/well of 
96-well flat-bottomed plates. Following overnight incubation, the cells were treated 
with Rh2 and PPD epimers or vehicle, containing 1:1000 dilution of Caspase-3/7 Green 
Detection Reagent (CellEvent™, Thermo Fisher Scientific) to detect apoptosis. To 
detect necrosis, 2.5 µg/mL PI was used. Drozitumab 100 ng/mL and staurosporine 0.25 
µM (Sigma-Aldrich) were used as positive controls for apoptosis in MDA-MB-231 and 
HUVEC, respectively [17, 18]. Drozitumab was freshly prepared by combining equal 
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volumes of 100 ng/µL of drozitumab (Genentech, South San Francisco, CA, USA) with 
100 ng/µL of affinity purified goat anti-human IgG Fcγ fragment (Jackson 
Immunoresearch Laboratories West Grove, PA, USA), incubating for 30 min at 4° C, 
and then diluting in culture medium for a final concentration of 100 ng/mL of 
drozitumab [18]. The number of positive cells for activation of caspase 3/7 or staining 
with PI was determined using an IncuCyte S3 Live-Cell Analysis System (Sartorius, 
Goettingen, Germany), acquiring four images per well every 2 h for 48 h. 
2.8. Molecular docking 
Crystal structures of VEGFR2 (2XIR and 3V2A), AQP1 (1FQY), AQP2 (4NEF), 
AQP4 (3GD8) and AQP5 (3D9S) were obtained from the protein data bank of NCBI 
(RCSB PDB). Canonical SMILES structures of Rh2 [19] and PPD [20] available on 
PubChem were used to prepare the 3D structure of each molecule in the UCSF Chimera 
program (version 1.15-mac64). The molecular docking was performed as previously 
described [11, 21], using UCSF Chimera program and Autodock Vina algorithm (version 
1.1.2_Mac_Catalina_64bit). The energies of interaction were predicted based on the 
flexible ligand docking simulations run within the docking grids on the intracellular 
side of the monomeric pores.  
2.9. VEGF bioassay 
VEGF Bioassay (Promega, Madison, WI, USA) was used to study the effects of S-
Rh2 on the activation of VEGFR2. This bioluminescent kit includes KDR/NFAT-RE 
HEK293 cells, in which activation of VEGFR2 triggers NFAT-RE-mediated 
luminescence. According to the manufacturer’s protocol, the cells were seeded in 
white, flat-bottom 96-well assay plates (Delta Surface TM, Thermo Scientific, Roskilde, 
Denmark). Cells received serial dilutions of S-Rh2 at a maximum final concentration 
of 100 µM, alone or in combination with VEGF-A (recombinant VEGF, Promega) at a 
constant final concentration of 35 ng/mL (80% effective concentration). Controls 
included bevacizumab and VEGF-A at the maximum final concentration of 6 µg/mL 
and 0.1 µg/mL, respectively. After 6 h of incubation, the cells were exposed to Bio-
Glo™ Reagent, incubated for 10 minutes and then the luminescence was read using 
the Optima plate reader. The relative luminescence units (RLU) in each well were 
subtracted from the background. The experiment was performed in duplicate. 
2.10. Statistical analysis 
One-way or two-way analysis of variance (ANOVA) was performed using GraphPad 
Prism version 9.0.0 for Mac, GraphPad Software, San Diego, California USA, 
www.graphpad.com. 
3. Results 
3.1. Rh2 and PPD inhibit the proliferation of HUVEC and MDA-MB-231 
The results of the anti-proliferative effects of epimers of Rh2 and PPD are shown 
in Figure 2, and the associated IC50 are presented in Table 1. In MDA-MB-231, 50 µM 
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(p = 0.007) and 100 µM (p = 0.0009) S-Rh2 significantly inhibited cell proliferation and 
in HUVEC, 12.5, 25, 50 and 100 µM (p < 0.0001) significantly inhibited cell proliferation. 
The IC50 for S-Rh2 was 59 µM in MDA-MB-231, while the IC50 in HUVEC was 9 µM, 
showing that HUVEC was more sensitive to the anti-proliferation effects of S-Rh2. 
 
Figure 2. Crystal violet assay on MDA-MB-231 and HUVEC cells exposed to 
0-100 µM of S-Rh2, R-Rh2, S-PPD or R-PPD for up to 3 days. Each data point 
represents mean ± SD of 6 replicates. * p = 0.01, ** p = 0.007, *** p < 0.001, **** p 
< 0.0001.  
R-Rh2 showed much less inhibitory action on MDA-MB-231 and HUVECs (Figure 
2) and IC50 values could not be calculated for this molecule, indicating that S-Rh2 is the 
active form of Rh2 responsible for its anti-proliferative action in these cells. Similar to 
S-Rh2, S-PPD was more effective on HUVECs. All of the tested concentrations of S-
PPD significantly inhibited the proliferation of HUVECs (p < 0.0001), while in MDA-
MB-231, only 50 µM (p = 0.0002) and 100 µM (p < 0.0001) significantly inhibited the 
proliferation (Figure 2). 
Table 1. The calculated half-maximal inhibitory concentration (IC50) causing 
reduced survival of MDA-MB-231 and HUVEC cells treated with S-Rh2, S-
PPD or R-PPD, at 72 h. 
 
IC50 (µM) (95% log confidence interval) 
S-Rh2 S-PPD R-PPD 
MDA-MB-231 59 (1.625-1.940)  50 (1.691-1.712) 16 (1.183-1.247) 
HUVEC 9 (8.619-8.644) 5 (0.7334-0.7334) 9 (0.9696-0.9696) 
IC50 values of S-PPD in MDA-MB-231 and HUVECs were 50 and 5 µM, 
respectively (Table 1). This showed that HUVECs were more sensitive to the anti-
proliferation effects of S-PPD. R-PPD, compared to S-PPD, was more potent on MDA-
MB-231. All tested concentrations of R-PPD significantly inhibited the proliferation of 
this cell line (p < 0.0001) (Figure 2). The IC50 of R-PPD in MDA-MB-231 and HUVEC 
was 16 µM and 9 µM, respectively (Table 1). R-PPD, at any concentration above 12.5 
µM significantly (p < 0.0001) inhibited the proliferation of HUVEC (Figure 2). 
Altogether, the above data suggested that HUVEC was more sensitive than MDA-MB-
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231 to the anti-proliferative effects of these molecules. Except for R-Rh2, all the other 
molecules showed effective inhibition of proliferation. In HUVEC, S-Rh2, S-PPD and 
R-PPD showed similar efficacies. In contrast, MDA-MB-231 was more sensitive to R-
PPD than S-Rh2 and S-PPD. 
3.2. Rh2 and PPD epimers induce cell death and cell cycle arrest 
In MDA-MB-231, the pattern of distribution of dead cells was different from 
HUVEC. Although a high proportion of MDA-MB-231 and HUVEC cells were located 
in quadrant (Q) 3 of the flow cytometry plot, annexin V-positive, MDA-MB-231 cells 
also had a distinct population in Q2 annexin V-/PI-positive, late apoptosis or 
necroptosis/necrosis (Figure 3). In these cells, 50 µM S-Rh2 did not induce cell death 
(Figure 3a) but increased cell cycle arrest in S phase by 34% (Figure 3b). At 100 µM (p 
= 0.0004) S-Rh2 induced approximately 80% cell death (Figure 3a) and increased cell 
cycle arrest in S phase by 99% (p < 0.0001) in the remaining 20% cells (Supplementary 
Figure 1). To determine whether the cells were undergoing apoptosis or necrosis, 
caspase 3/7 reagent was used to detect the activation of apoptosis or with PI to detect 
loss of cell membrane integrity (Figure 4). At 50 and 100 µM S-Rh2, no activation of 
caspase 3/7 was observed (Figure 4a). In contrast, at 100 µM a rapid increase in PI 
staining was observed, consistent with the observed cell death. These findings suggest 
that the annexin V-positive MDA-MB-231 cells observed following S-Rh2 treatment 
are not due to induction of apoptosis but are likely to be the result of a loss in 
membrane integrity. Necroptosis is a caspases-independent programmed cell death, 
in which similar to apoptotic cells, phosphatidylserine in the cell membrane is flipped 
and cell rupture results in the release of DAMPs recruiting immune cells to also 
prompt a non-inflammatory cell death [22, 23]. In vitro and in the absence of immune 
cells and phagocytosis, the cell membrane of late necroptotic cells becomes leaky and 
the cells become positive for both annexin V and PI [24]. The rapidly increased PI 
staining induced by 100 µM S-Rh2 in MDA-MB-231 might indicate a 
necroptotic/necrosis phenomenon or a combination of both.  
In HUVEC, 50 and 100 µM S-Rh2 rapidly (within 2 h) induced activation of caspase 
3/7 (Figure 4c) and loss of membrane integrity (Figure 4d). The count of positively 
stained cells reduced over time and examination of the images revealed that this was 
due to progressive disintegration of the positive cells. After 3 days of treatment, the 
majority of the remaining cells (71% for 50 and 100 µM) were annexin V-positive/PI-
negative (Figure 3c). These remaining cells had arrested at S phase and the G2/M 
population had disappeared (Figure 3d, Supplementary Figure 1). Overall, results 
showed that S-Rh2 was an inducer of necrosis in MDA-MB-231 and apoptosis in 
HUVEC. 
In both cell types, R-Rh2 caused a minimal increase in annexin V/PI staining 
(Figure 3a and 3c), indicating a minimum induction of cell death, consistent with the 
results of proliferation assay (Figure 2) and the caspase 3/7 and PI experiments (Figure 
4). It induced cell cycle arrest in S phase by about 40% (p < 0.0001) in MDA-MB-231 
and cell cycle arrest in G0/G1 phase in HUVEC by about 3% (p < 0.01) suggesting that 
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cell cycle arrest is a dominant mechanism of this molecule in inhibition of proliferation 
(Supplementary Figure 1). 
 
 
Figure 3. Analysis of (a) cell death and (b) cell cycle arrest in MDA-MB-231 
cell line and (c) cell death and (d) cell cycle arrest in HUVEC following a three-
day exposure to S-Rh2, R-Rh2, S-PPD, and R-PPD. Each data point represents 
mean ± SD of three replicates. All comparisons are between the treatments and 
the vehicle control cells, p < 0.05. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p 
< 0.0001. 
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In MDA-MB-231, 50 and 100 µM S-PPD induced a significant increase in the 
proportion of cells that stained annexin-positive (Figure 3a). S-PPD did not induce 
caspase 3/7 activation in MDA-MB-231 (Figure 4a). Instead, it significantly increased 
the PI count within 4 h with 100 µM (p < 0.0001) and 12 h with 50 µM (p = 0.0002) 
(Figure 4b), suggesting that it induced a necroptotic/necrotic cell death.  
 
Figure 4. Mode of cell death in MDA-MB-231 and HUVEC cells exposed to 
Rh2 and PPD epimers. (a) and (c) show activation of caspase 3/7 in MDA-MB-
231 cells, and HUVEC respectively. White arrows pointing at red dots show 
activation of caspase 3/7 in cells. (b) and (d) show staining of cells PI in MDA-
MB-231 and HUVEC cells, respectively. Blue spots indicate cells positive for 
PI. Staurosporine or drozitumab were used as positive controls. Scale bars 
show 400 µm. Each data point represents mean ± SD of 8 replicates. 
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In HUVEC, a significant increase in annexin V-positive/PI-negative cells (Figure 
3c), and an increase in the caspase 3/7-positive cell count, which peaked at 8 h with 100 
µM and 10 h with 50 µM (Figure 4c), was observed. The increase in the caspase 3/7 cell 
count was closely followed by a significant increase in PI-positive cell count (Figure 
4d). 
R-PPD was the most potent anti-proliferative molecule in MDA-MB-231 (Table 1). 
At 25 µM (p = 000.9) and 50 µM (p = 0.0001), R-PPD, in a concentration-dependent 
manner, induced 53% and 83% cell death (Figure 3a) and 30% cell cycle arrest in S 
phase (Supplementary Figure 1). Similar to other studied epimers, R-PPD did not 
induce activation of caspase 3/7 in MDA-MB-231 (Figure 4a) but increased PI staining, 
dose-dependently (Figure 4b). This could indicate that R-PPD is also an inducer of 
necroptotic/necrotic cell death in this cell line. In HUVEC, R-PPD induced 95% cell 
death at both tested concentrations (p < 0.0001), and 15% cell cycle arrest in G0/G1 
(Supplementary Figure 1), accompanied by a gradual increase in caspase 3/7 activation 
and PI count, indicating apoptosis. Overall, these findings suggest that S-Rh2, S-PPD 
and R-PPD induced necroptosis/necrosis in MDA-MB-231 and induced apoptosis in 
HUVEC. These molecules induce S-phase arrest in MDA-MB-231 and G0/G1 arrest in 
HUVEC. 
3.3. S-Rh2 is the most potent inhibitor of loop formation 
Figure 5 shows the results of loop formation assay following exposure with 
ginsenosides. Vehicle treated HUVEC formed clear loops with elongated cells. Among 
the four tested molecules, S-Rh2 was the most potent in inhibiting loop formation. At 
100 µM, cell migration was completely inhibited, and no loops were formed (p < 
0.0001), which could be due to the rapid cell death induced by this drug (Figure 4c and 
4d). At lower concentrations of S-Rh2 loop formation was also significantly inhibited 
(p < 0.0001). The results indicate that the mechanism by which S-Rh2 inhibits loop 
formation might be different at different concentrations. At 1 µM, though the 
concentration was very low, the cells made deformed and unusual loops. This low 
concentration, after two days of exposure, increased the activation of caspase 3/7 
(Supplementary Figure 2). At 10 µM no significant induction of cell death was 
observed in the cells (Supplementary Figure 2) and the cells survived on Matrigel. As 
shown in Figure 4c and 4d, 50 µM SRh2 induced significant cell death in HUVEC 
within the first 2 hours, which could be considered as the major anti-loop formation 
mechanism of this drug. Based on the number of loops formed, a dose-dependent 
reduction in loop formation was observed in the 10-100 µM range (p < 0.0001). 
R-Rh2 did not show any biologically relevant inhibition of proliferation (Figure 2) 
but showed some level of inhibition of loop formation at 10 (p = 0.0003), 50 (p = 0.0001) 
and 100 µM (p < 0.0001). However, unlike S-Rh2, at 1 µM R-Rh2 had no efficacy on 
loop formation. S-PPD and R-PPD showed a U-shaped dose-response curve in loop 
formation assay, showing inhibition of loop formation only in lower concentrations.  
 




Figure 5. (a) Loop formation assay in HUVEC cells following exposure to S-
Rh2, R-Rh2, S-PPD, and R-PPD, (b) schematic structure of VEGFR2 showing 
the extracellular domain, VGEF binding site, a transmembrane domain, 
intracellular domain and the ATP-binding pocket of VEGFR2. Molecular 
docking of S-Rh2 with (c) VEGF-binding site and (d) the ATP-binding pocket 
of VEGFR2, and the dose-response curves relating to the action of (d) 
bevacizumab, (e) VEGF and S-Rh2 with or without VEGF in the VEGF 
bioassay system are shown. Each data point represents mean ± SD of two or 
three replicates. All comparisons are between the treatments and the vehicle 
control cells, p < 0.05. 
3.4. VEGFR2 and AQP1 as potential targets of Rh2 
To screen for the possible targets of Rh2 and PPD, molecular docking was 
performed. A key driver of angiogenesis is the interaction between VEGF and 
VEGFR2, so the interaction of Rh2 and PPD with VEGFR2 was studied. VEGFR2 has 
two major binding sites, the ATP-binding pocket and the VEGF-binding site (Figure 
5b), both of which were studied in this molecular docking. As shown in Table 2, both 
Rh2 and PPD were predicted to have a better interaction with the ATP-binding pocket 
than with the receptor. PPD was predicted to have a better binding score with this site 
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of VEGFR2. However, given the U-shaped dose-response curve of PPD on loop 
formation of HUVECs, it is difficult to conclude whether this interaction is inhibitory 
or stimulatory.  
Table 2. Binding scores (number of H bonds) of Rh2 and PPD with different 
aquaporin water channels, ATP-binding pocket or the VEGF-binding site of 
VEGFR2. 
Molecules 
Binding score (kJ/mol) (number of H-bonding) 
VEGFR2*  VEGFR2** AQP1 AQP2 AQP4 AQP5 
Rh2 -7.6 (1) -7.1 (2) -8.1 (2) -5.2 (1) -6.3 (3) -8.1 (4) 
PPD -8.2 (1) -6.9 (1) -8.4 (0) -6.9 (0) -5.6 (0) -7.7 (1) 
*ATP-binding pocket of the receptor **VEGF binding site of the receptor 
Figure 5c and 5d show the interaction sites of Rh2 with VEGF-binding site and the 
ATP-binding pocket of VEGFR2, respectively. To test the interaction of S-Rh2 with 
VEGFR2 in vitro, a VEGF bioassay was performed. In this assay, upon the activation 
of VEGFR2 with its ligand, the cells luminesce and in the presence of an inhibitor such 
as bevacizumab, the luminescence is inhibited. In this assay, bevacizumab, which was 
used in the presence of VEGF, showed an IC50 of 0.11 µg/mL (Figure 5e). S-Rh2 was 
used with no VEGF to see if it has a stimulatory action on the receptor. In this state, a 
steady luminescence was detected except at 100 µM. Since Rh2 is highly cytotoxic at 
100 µM, the reduced luminescence from the cells at this concentration could be due to 
cell death. S-Rh2 alone did not affect the activation of the receptor, but in the presence 
of VEGF, S-Rh2 shifted the dose-response curve of VEGF to right (Figure 5f), indicating 
that S-Rh2 potentially acted as an allosteric modulator of the receptor, binding to the 
allosteric site, changing the conformation of the receptor and as a result, decreasing 
the affinity and potency of VEGF on this receptor. 
Furthermore, molecular docking was performed with four members of the 
aquaporin family, AQP1, AQP2, AQP4 and AQP5. AQPs have a homo-tetramer 
structure where each monomer is responsible for the transport of water. Each 
monomer consists of six transmembrane domains (M1-M6) and three loops (B, D and 
E) (Figure 7a). Loops B and E are responsible for water transport function of the 
channel [25]. Figure 7b-7e shows the molecular docking of Rh2 and PPD into AQP1 
and AQP5. Rh2 had good binding scores with both AQP1 and AQP5, with binding 
scores of -8.1 kJ/mol (Table 2). With AQP1, Rh2 made two H-bonds at HIS-67 and VAL-
72 (Figure 7b) of loop B (water pore) [25]. With AQP5, it made 4 H-bonds at M2, loop 
B (Pro 795, Arg-819 (2), and GLN-814. PPD had a better binding score with AQP1 (-8.4 
kJ/mol) (Table 2). However, molecular docking showed no H-bonds between the two 
molecules which might suggest a loose binding compared to that of Rh2. With AQP5, 
PPD showed a single H-bond with ASN-961 in M6.  
As shown in Figure 7, both Rh2 and PPD showed a better blocking of AQP1. The 
surface views suggest that both Rh2 and PPD fit inside the water channel and 
completely block the passage of water. In the case of AQP5, though the binding scores 
and number of H-bonds are encouraging, the molecules seem to attach to one side of 
the water channel and leaving the water passage open (Figure 7c and 7d). Functional 
assays are required to confirm these in silico findings.  





Figure 7. (a) Schematic structure of a monomer AQP1 showing 
transmembrane domains (M1-M6), loops B and E responsible for water 
transport and loop D. Molecular docking of (b) Rh2 and (c) PPD in AQP1 and 
molecular docking of (d) Rh2 and (e) PPD in AQP5. Rh2 makes two H-bonds 
with HIS-67 and VAL-72 of loop B (water pore).  
4. Discussion 
Ginsenoside Rg3 has long been a candidate for investigation as an anticancer drug. 
Several studies have shown that Rg3 epimers have stereoselective activities [11, 26, 27]. 
Also, preclinical studies have shown the efficacy of Rg3 for the treatment of breast 
cancer [11, 28, 29]. In China, Rg3 is a registered anti-angiogenic agent. Several studies 
have shown that oral or parenteral administration of Rg3 leads to the metabolism of 
Rg3 (reviewed in [1]), leaving mainly active metabolites in the body. Peng et al. (2016) 
showed that following either of the routes of administration of Rg3 epimers, two major 
deglycosylated metabolites were produced; SRg3 produced S-Rh2 and S-PPD, and 
RRg3 produced R-Rh2 and R-PPD [30]. In this study, looking for treatment options for 




These molecules have been a subject of several studies. S-Rh2 showed efficacy 
against acute promyelocytic leukemia [31], T-cell acute lymphoblastic leukemia [32] 
and colon cancer models [33], in vitro. There is a lack of literature on the anticancer 
efficacy of R-Rh2: it was shown that only S-Rh2 and not R-Rh2 inhibited the 
proliferation of prostate cancer cell lines [35]. Similar to that result, we showed that in 
MDA-MB-231 and HUVEC, S-Rh2 had a more profound anti-proliferative effect. PPD 
has also been a subject of some studies. S-PPD induced apoptotic cell death in 
endometrial cancer cells [36], fibrocarcinoma cells [37], colorectal adenocarcinoma 
cells [38, 39], breast, prostate and osteosarcoma cell lines [39]. Injection of 30 mg/kg 
PPD (every 2 days for 3 weeks) to a xenograft mouse model of colorectal cancer 
showed a significant decrease in tumour size in this model [39]. In colorectal cancer 
cells, PPD showed anti-proliferative effects via induction of G1/S cell cycle arrest and 
targeting MAPK and NF-κB signalling [39]. This was in agreement with our finding 
showing S-PPD induced G1 cell cycle arrest in MDA-MB-231.  
We have shown that S-Rh2 is a more potent anti-proliferative molecule compared 
to its R counterpart. This is similar to the effects observed with SRg3, being the only 
epimer that inhibited the proliferation of MDA-MB-231 [11]. We have shown that 
except for R-Rh2, three other ginsenosides have anti-proliferative effects in the tested 
TNBC cell line. In this cell line, the most potent molecule was R-PPD with an IC50 of 16 
µM. Choi et al. (2009) studied the effects of Rh2 (unspecified epimer) on two breast 
cancer cell lines, MCF-7 and MDA-MB-231 [40]. In their studies, in a 48-h exposure to 
40 µM Rh2, a slight increase in G1 population of cells was observed. They showed that 
the Rh2-induced cell cycle arrest was via p15 and p27-dependent inhibition of kinase 
activities of G1-S specific Cdks/cyclin complexes [40]. Their result may not be 
completely comparable with ours due to lack of specification of the epimer used and 
the difference in the exposure time. However, it is possible to conclude that in lower 
concentrations and shorter exposure times (such as 48 h), S-Rh2 might induce cell cycle 
arrest and this cell cycle arrest might lead to cell death in longer exposure times (such 
as 72 h in our experiment).  
The anti-proliferative concentrations of these molecules significantly increased 
annexin V/PI staining, as an indicator of cell death. Kwak et al. (2014) showed that S-
PPD at a short-time exposure and a low concentration (2.5 and 5.8 µM, 24 h) induced 
apoptosis in MDA-MB-231 via activation of caspase-8, -3 and poly ADP-ribose 
polymerase [41]. We looked at the mechanism of cell death induced by higher 
concentrations of all four molecules. At high concentrations, in MDA-MB-231, S-Rh2, 
S-PPD and R-PPD induced cell death as indicated by both annexin V positive and 
annexin V/PI positive subpopulations. For the first time, we showed that the 
mechanism of cell death induced in MDA-MB-231 at these concentrations is not 
apoptosis, but a necroptotic/necrotic cell death. The R enantiomer of alkanin, known 
as shikonin, was the first reported inducer of necroptosis [42, 43] and these 
ginsenosides, if confirmed with complementary experiments, could be another group 
of natural inducers of necroptosis.  
Similar to apoptotic cells, in necroptotic cells phosphatidylserine is flipped to the 
outer bilayer cell membrane [44] and hence, the cells are stained positive for annexin 
V. Necroptosis is a regulated process, which unlike apoptosis, is caspase 3/7 
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independent. The induction of necroptosis is usually dependent on the activation of 
tumour necrosis factor (TNF) receptor superfamily, interferon receptors, T-cell 
receptors and Toll-like receptors [45]. Genotoxic stress and anti-cancer agents such as 
shikonin are also amongst the inducers of necroptosis [45]. Shikonin was shown to 
overcome cancer drug resistance [43, 46] and inhibit osteosarcoma-induced lung 
metastasis [47] via induction of necroptosis. The role of necroptosis in cancer treatment 
has been widely discussed in recent years. It is important to remember that different 
types of programmed cell death, including apoptosis, necroptosis and autophagy, 
might coexist with one playing a dominant role. This paper shows for the first time 
that, in MDA-MB-231, these molecules do not induce apoptosis but are potential 
inducers of necroptosis/necrosis.  
Our results demonstrated that HUVECs were a more sensitive target for the anti-
proliferative action of these molecules, a finding relevant to their anti-angiogenic 
activity. We showed that S-PPD and R-PPD have IC50 values of about 5 and 11 µM in 
HUVECs, respectively, which are close to the values reported by Usami et al. (S-PPD: 
5 µM and R-PPD: 14 µM) [48]. We showed that both epimers are strong inducers of 
apoptosis in HUVECs, however, with different rates. S-PPD induces the activation of 
caspase 3/7 more rapidly; a process that is more gradual with R-PPD. Wang et al. 
showed that S-PPD induces apoptosis via endoplasmic reticulum stress by activating 
protein kinase R‑like endoplasmic reticulum kinase (PERK)‑eIF2α signalling pathway 
[49]. They used up to 20 µM S-PPD and concluded that high concentrations of S-PPD 
could be used for the treatment of angiogenesis‑related diseases. Our results with the 
loop formation assay showed that S-PPD and R-PPD have U-shaped dose-response 
curves. This U-shaped dose-response curve was also reported for Rg3 epimers. As 
reviewed before [2], Rg3 at nM concentrations had anti-angiogenic properties, at low 
µM ranges, such as 10-15 µM, had proangiogenic effects and at high µM 
concentrations showed anti-angiogenic effects. It should also be considered that the 
observed effects on loop formation are a cells' immediate response to these agents. 
With pretreated cells, it is expected that the anti-loop formation effects of drugs be 
much increased. As shown in the proliferation assay, in a three-day exposure, low and 
high concentrations of the drugs considerably inhibited proliferation. Therefore, it 
could be concluded that, the molecules are very potent anti-angiogenic agents. We also 
tested the anti-proliferative effects of these four molecules at nM and low µM ranges 
in HUVECs (Supplementary Figure 3). Unlike the reported effects for Rg3 (reviewed 
in [2]), these molecules do not have anti-proliferative effects at such low concentrations 
in HUVEC, although, after 2 days of exposure to 1 µM S-Rh2, evidence of activation 
of caspase 3/7 is observed (Supplementary Figure 2). 
Our results showed that Rh2 had a better immediate anti-angiogenic action. 
Amongst the four molecules, S-Rh2 was the most potent molecule in inhibition of loop 
formation. An unspecified epimer of Rh2 was studied by Zhang et al. [50] for its anti-
angiogenic properties. They showed that Rh2 inhibited the proliferation of HUVECs 
only at high doses (>125 µM), but pretreatment of cells with 1 and 10 µM Rh2 
significantly inhibited the VEGF-induced cell proliferation and migration. They 
showed that 10 µM Rh2 decreased the activation of GRB2-associated-binding protein 
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1 (Gab1), vascular endothelial growth factor receptor 2 (VEGFR2), protein kinase B 
(PKB or AKT) and extracellular signal-regulated kinase 1/2 (ERK 1/2) [50]. We showed 
that 10 µM S-Rh2 caused small levels of decrease in the expression of AQP1 and 
activation of focal adhesion kinase (FAK) (Supplementary Figure 4), which could 
contribute to the anti-angiogenic properties of this drug. Also, preliminary data show 
that at this concentration, S-Rh2 caused a non-significant reduction in the size of MDA-
MB-231 mammospheres (Supplementary Figure 5). This effect, which might indicate a 
looser cell-cell connection in these mammospheres, could be further exacerbated in 
higher concentrations.  
To investigate potential targets of these molecules, we performed molecular 
docking on some of the candidate proteins. The interaction between VEGF-VEGFR2 
plays a crucial role in induction of angiogenesis. For the first time, using molecular 
docking we showed that there is a good binding score between these molecules and 
VGEFR2. VEGF bioassay showed that Rh2 shifted the dose-response curve of VEGF to 
the right. The extracellular domain of VEGFR2 consists of seven immunoglobulin (Ig) 
homology domains; D1 to D7 are located at the N-terminus to the closest to the cell 
membrane, respectively. D2-3 domains have the highest affinity for VEGF and D4-7 
reduce binding affinity by about 10 fold, playing role in regulating the activation and 
function of the receptor [51]. The intracellular domain of VEGFR2 is responsible for 
the kinase activity and downstream signalling. Small-molecule kinase inhibitors such 
as sunitinib compete with ATP and interact with the ATP-binding pocket of the 
intracellular domain [52]. Adjacent to this orthosteric ATP-binding site, there is an 
allosteric site [53]. Despite the good binding score of Rh2 and PPD with ATP-binding 
pocket of VEGFR2, S-Rh2 alone did not stimulate or inhibit the receptor. The only 
exception was the highest concentration used (100 µM) which is a cytotoxic 
concentration. In the presence of VEGF, S-Rh2 shifted the dose-response of VEGF to 
the right. This is typical of allosteric modulators. Unlike orthosteric ligands that bind 
to their agonist-binding site and initiate downstream signalling, allosteric ligands bind 
to distinct sites distant from the orthosteric site, change the conformation of the 
receptor and change the efficacy of the orthosteric ligands or function of the receptor 
[53]. Our preliminary studies have not shown whether S-Rh2 changes the affinity of 
VEGF or the function of the receptor, but we have shown that S-Rh2 in the presence of 
high concentrations of VEGF (EC75), reduced the activation of VEGFR2. This could be 
particularly important in the hypoxic regions of a tumour when angiogenesis is 
occurring, and high levels of VEGF exist. 
AQPs were another target of screening in this study. AQPs are primarily 
responsible for the transport of water across the cell membrane. AQP1, AQP2, AQP4 
and AQP5, the AQPs for which a human crystal structure is published, were 
investigated in this study. Molecular docking showed that Rh2 and PPD have good 
binding with AQP1 and AQP5, both of which play roles in cancer. AQP1 and AQP5 
play roles in proliferation, migration, invasion and angiogenesis (reviewed in [2, 12]). 
Both of these AQPs localize at the leading edge of a migrating cell and facilitate cell 
migration. Despite the good binding score of these ginsenosides with AQP5, the water 
transport function of AQP5 channel might not be effectively blocked by these 
molecules. Based on molecular docking data, Rh2 and PPD seem to be a better blocker 
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of AQP1 water channel. In comparison, Rg3 had a better binding score with AQP1 (-
9.4 kJ/mol) [11]. The binding score of Rh2 and PPD is also weaker than those of other 
known blockers of AQP1 with saponin structure, such as bacopaside I and II [54]. 
Using oocyte expression assay, we showed that Rg3 epimers have stereoselectivity in 
blocking AQP1 water channel; SRg3 is a selective blocker of AQP1 [11]. Whether the 
epimers of Rh2 and PPD have a similar stereoselectivity needs further investigations. 
Also, in molecular docking studies, Rg3 was more selective for AQP1 and did not show 
a good binding score with AQP5. Considering the current results of molecular 
docking, it is possible to conclude that upon administration of Rg3 and production of 
its metabolites, these ginsenoside could work together and contribute to the observed 
anti-cancer activities of Rg3. Blocking the water channel function of AQP1 may have 
an immediate role in inhibition of loop formation and anti-angiogenic effects of Rh2.  
In conclusion, we have shown that metabolites of Rg3 are more potent anti-
proliferative agents than Rg3. They are potential inducers of S-phase arrest and 
necroptosis in MDA-MB-231 and inducers of G0/G1 arrest and apoptosis in HUVEC. 
S-Rh2 was a most potent anti-angiogenic agent and it was shown that S-Rh2 had 
allosteric modulatory action on VEGFR2 function. Rh2 and PPD have the potential of 
blocking AQP1 and AQP5. Altogether, these data suggest that metabolites of Rg3 
could potentially increase the anti-cancer properties of Rg3, in vivo. Single or 
combination of these molecules could be considered as potential anti-cancer treatment 
options for future studies. 
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Appendix A. Supplementary data 
 
Supplementary Figure 1. The effect of Rh2 and PPD epimers on cell cycle, 
excluding the sub-G1 cells. The experiment was performed in triplicate and 
the data are shown as mean ± SD of three replicates. All comparisons are 
between the treatments and the vehicle control cells, p < 0.05. * p < 0.05, ** p < 
0.01, *** p < 0.001 and **** p < 0.0001. 
 
Supplementary Figure 2. Effect of 1 and 10 µM S-Rh2 on the (a) activation of 
caspase 3/7 (red spots) or (b) staining with PI (blue spots) in HUVEC cells in a 
3-day study. After 2 days of exposure, a significant increase in the activation 
of caspase 3/7 is observed with 1 µM S-Rh2. Each datapoint represents mean 
± SD of 8 replicates. All comparisons are between the treatments and the 
vehicle control cells, ** p = 0.0068. 




Supplementary Figure 3. The effect of low concentrations of Rh2 and PPD 
epimers on the proliferation of HUVEC cells. Each datapoint represents mean 
± SD of 6 replicates. All comparisons are between the treatments and the 
vehicle control cells, p < 0.05. 
 
Supplementary Figure 4. (a) Expression of AQP1 and (b) activation of focal 
adhesion kinase (FAK) following a 3-day exposure with 10 µM S-Rh2. Total 
cell lysates were prepared, and 50 µg total protein was used for Western 
blotting. The antibodies used for immunostaining included anti-AQP1 
antibody [EPR20325] (ab219055, Abcam, Cambridge, UK, 1:1000), anti-FAK 
antibody [EP6954] (ab40794, Abcam, Cambridge, UK, 1:1000), anti-phospho 
FAK antibody [EP2]60Y] phosphor Y397 (ab 81298, Abcam, Cambridge, UK, 
1:1000) Goat anti-rabbit IgG H&L (HRP) (ab6721, Abcam, Cambridge, UK, 
1:3000) was used as the secondary antibody. 
 
Supplementary Figure 5. Effect of 10 µM S-Rh2 on the formation of MDA-MB-
231 mammospheres. MDA-MB-231 cells, at 4000 cell/cm2 of 24-well ultra-low 
attachment plates, were grown as mammospheres using MammoCult™ 
Human Medium Kit (Stem Cell Technologies, Vancouver, Canada), exposed 
to vehicle or 10 µM S-Rh2. After 4 days, the number of mammospheres larger 
than 50, 100 and 150 µm was counted. The experiment was performed in 
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Chapter 6 Conclusion 
In the research conducted for this thesis, an evaluation of combined Rg3 epimers was 
performed as a treatment option for TNBC. A series of experiments were conducted 
not only to produce novel experimental data on the optimisation of a combination of 
SRg3 and RRg3, but also to test the efficacy of this combination using in silico, in vitro 
and in vivo models. The following sections demonstrate the significance of this study 
and make some recommendations for future studies.  
6.1. Significance of the presented study 
In this project, a thorough and deep literature review was performed considering 
pharmacokinetic, pharmacodynamic and toxicity aspects of administering this drug. 
Furthermore, a comprehensive review was performed on TNBC, the currently 
available treatment options, the success rates of the current treatments and the 
potential targets for the treatment of this disease. Based on this background and 
preliminary in silico molecular docking studies between ginsenoside molecules and 
AQP1, lab-based experiments were performed and a novel candidate for the treatment 
of TNBC was introduced. The first important contribution of this project was to show 
the stereoselectivity of Rg3 epimers and their blocking effect on AQP1. This led to the 
second significance of this project, optimising the combination of the drugs for their 
anti-cancer actions. The following conclusions were drawn: 
1. It is known that AQP1 plays several roles in cancer progression. It is involved 
in cell proliferation, migration, invasion and angiogenesis. Specifically, 
overexpression of AQP1 is correlated with worse prognosis of TNBC, higher 
tumour grade and lower overall survival. In this research, for the first time, 
using in silico molecular docking, the interaction between Rg3 and AQP1 water 
channel was shown. This indicated that Rg3 had potential as a treatment option 
for TNBC. Further studies using in vitro oocyte swelling assay showed that only 
SRg3 blocked AQP1-mediated water transport function of AQP1. Rg3 epimers 
were not potent inhibitors of cell proliferation in TNBC in vitro models and only 
SRg3 inhibited the proliferation of MDA-MB-231, a mesenchymal basal-like cell 
line. SRg3 and RRg3, differently inhibited cell migration in 2D and 3D models 
and only RRg3 inhibited invasion of these TNBC cells. The overall conclusion 
of these studies was that Rg3 epimers have stereoselective efficacies in these 
models and could be considered as separate drugs. 
2. In several published studies, Rg3 was extracted in experimental settings, 
without sufficient information on the purity and the type of specific epimer 
used. Extraction procedures might lead to different ratios of SRg3 and RRg3, 
and considering the stereospecific functions of Rg3, it is critical to identify the 
purity of specific epimers and the ratio between them. In the current study, the 
effects of purified (> 98%) epimers were investigated. Following demonstrating 
the stereoselectivity of the epimers in TNBC models, for the first time, an RSM 
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model was developed to optimise the combination of SRg3 and RRg3. The 
optimised combination showed efficacy on endothelial and TNBC cells. 
Furthermore, it was shown that in HUVEC, these epimers as a single agent, did 
not induce apoptosis, but potentiate each other in combination and induced 
apoptosis in a dose-dependent pattern. 
3. A critical aspect of the action of any investigational drug candidate in 
preclinical studies is to show time- and dose-dependency in its actions. In this 
research, combinations of SRg3 and RRg3 were studied at two time-points on 
loop formation and migration of endothelial cells. It was shown that Rg3 
combinations followed these basic principles of pharmacokinetics.  
4. The key driver of angiogenesis is the interaction of VEGF and VEGFR2. 
Previously, some studies suggested that Rg3 had inhibitory effects on the 
expression of VEGF and hence affected angiogenesis. For the first time, in this 
research, the interaction of Rg3 epimers with VEGFR2 was studied. It was 
shown that Rg3 epimers had allosteric modulatory action on the dose-response 
curve of VEGF. Allosteric modulators, due to higher target-specificity and 
lower toxicity profile, are of special interest to pharmaceutical industries. 
5. The optimised combination of Rg3 epimers showed the best efficacy on AKT 
signalling in endothelial cells grown in normoxia. For endothelial cells grown 
in hypoxia, the treatment affected AKT signalling and also decreased VEGF 
expression, which has a great impact on angiogenesis.  
6. The optimised combination also affected AKT signalling in TNBC cell lines. 
These cells were grown as mammospheres, which are enriched with cancer 
stem cells and compared to 2D models of cell culture, are a better representation 
of a human breast tumour. For the first time, the effect of the combination of 
Rg3 epimers was studied on mammospheres. This study showed that the 
optimised combination of Rg3 epimers also decreased the ‘stemness’ of TNBC 
cells via decreased expression of CD44 and decreased ratio of CD44/CD24. 
Cancer stem cells play several roles in cancer progression and resistance to 
treatment. The proposed treatment could decrease the expression of stem cell 
markers and reduce the invasiveness of the disease. 
7. Based on the results achieved from the effects of Rg3 on AKT signalling, the 
common proteins that were affected were those that were related to mTOR 
signalling. Further in silico molecular docking studies showed that Rg3 epimers 
could be potential mTOR inhibitors, as they have good binding with the 
rapamycin binding site of mTOR and block the interaction site of Rheb, the 
mTOR activator protein. Considering the importance of PI3K/AKT signalling 
inhibitors in general and specifically mTOR inhibitors in the treatment of TNBC 
patients, inhibition of this signalling by Rg3 could be considered an important 
mechanism with potential clinical efficacy in these patients.  
8. The in vivo model of metastatic TNBC used in this study was a highly aggressive 
model and metastasised tumour cells were detectable in mice as early as two to 
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three weeks after tumour cell injection. Secondary tumours were detectable 
with IVIS before the treatment started. Despite this, the treatment could 
significantly inhibit the growth of the primary tumour and secondary tumours, 
which is a significant finding in such an aggressive tumour model. In future 
research, the study could be modified by reducing the number of cells injected 
into the mammary fat pad and commencing treatment sooner. 
9. Several studies showed that Rg3 epimers are prone to extensive metabolism, 
which is more evident with the orally administered drug. The major active 
metabolites of Rg3 are deglycosylated forms of Rg3; epimers of Rh2 and 
epimers of PPD. To find out if these molecules have any contribution to the anti-
cancer effects of Rg3, some preliminary testing was performed on a TNBC and 
an endothelial cell type. For the first time, the results of this study compared the 
anti-proliferative effects of Rg3 epimers and its deglycosylated metabolites and 
showed that unlike Rg3, its metabolites are potent anti-proliferative agents. 
While only SRg3 at 100 µM showed anti-proliferation effects on MDA-MB-231, 
its metabolites, except R-Rh2, had a dose-dependent anti-proliferative action at 
6.2-100 µM range. The other difference between these molecules and their 
metabolites are their anti-proliferative mechanism. With SRg3, the main anti-
proliferative mechanism was cell cycle arrest at G0/G1 and with the metabolites, 
the major cell death mechanism was a necroptotic cell death. In addition, S-Rh2 
could also contribute to the effects of Rg3 on mammosphere formation and 
stemness of the cells. The different mechanisms involved suggests that a 
combination of all of these molecules could contribute to the observed anti-
cancer effects of Rg3. 
10. The anti-angiogenic effects of these deglycosylated molecules were also studied 
in HUVEC. Except for R-Rh2, these molecules potently (IC50 < 10 µM) inhibited 
the proliferation of HUVEC. These deglycosylated molecules or the parent 
drug, all activated caspase 3/7 and induced apoptosis in these cells.  The most 
potent anti-loop formation agent was S-Rh2. The anti-loop formation 
mechanisms of this molecule at different concentrations were different. At high 
µM concentrations, such as 50 and 100 µM, apoptotic cell death prevailed, but 
at 1 and 10 µM, other anti-migration mechanisms could be involved in 
inhibiting loop formation.  
11. To investigate the anti-migration effects of these molecules, the interaction of 
Rh2 and PPD with VEGFR2 and AQPs was studied. For the first time, in this 
project, it was shown that S-Rh2, similar to its parent drug, had allosteric 
modulatory action on VEGFR2, which suggests that S-Rh2 also contributed to 
the anti-angiogenic effects of Rg3. Furthermore, molecular docking results 
suggested that these molecules are a better blocker for AQP1 rather than AQP5. 
Both AQP1 and AQP5 localise at the leading edge of migrating cells and 
facilitate cell migration.  
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12. One outcome of this research was that, either with Rg3 epimers or its 
metabolites, endothelial cells were more sensitive to the anti-proliferative 
effects of either Rg3 epimers or its metabolites. This might suggest that the 
principal function of these molecules might be anti-angiogenic action, with 
other mechanisms acting on TNBC cells such as inhibition of AKT signalling.  
6.2. Recommended future work 
In this thesis, a novel treatment for TNBC patients was proposed. This treatment 
included a combination of SRg3 and RRg3, which was optimised in RSM models.  The 
efficacy of this treatment on in vitro angiogenesis and TNBC models and in an in vivo 
metastatic model of TNBC was demonstrated and some of the mechanisms of action 
of this drug were proposed. Furthermore, this project investigated the efficacy of 
deglycosylated metabolites of Rg3 and suggested a possible contribution of these 
molecules to the observed anti-cancer effects of Rg3. However, despite the significant 
knowledge developed in this field, some gaps exist that could be considered for further 
investigation and pave the way for the commercialisation of these findings. Some 
recommendations are as follows: 
1. Contribution of AQP1 to the anti-angiogenic effects of the drugs 
Preliminary in silico molecular docking studies on the interaction of Rh2 and 
PPD with AQP1 showed promising results and oocyte swelling assay could be 
performed to confirm the blocking effect of these molecules. Using this assay, it 
was shown that SRg3 was a blocker of AQP1 water transport. A growing body 
of evidence shows the role of AQP1 in angiogenesis and cancer progression. In 
this thesis, it was shown that the expression of AQP1 in endothelial cells was 
decreased in long-term exposure to Rg3. However, the drugs showed 
immediate anti-loop formation effects on non-pretreated cells, too. It could be 
hypothesised that blocking AQP1 was responsible for that immediate effect. 
Further studies on endothelial cells could test whether blocking AQP1 plays a 
major role in anti-angiogenic action of Rg3. In addition, further studies could 
study the mechanisms of anti-loop formation effects of S-Rh2. 
2. Further in vivo animal studies 
i. In the current study, an immunocompromised mouse model was used to 
study the efficacy of the proposed drug. This model had some advantages 
including growing human tumour cells and developing metastasis. 
However, being an immunocompromised model, the interactions of the 
immune system with the tumour and the treatment is lacking. Considering 
the fact that Rg3 epimers have been shown to improve immune function in 
animal models and the important role of the immune system in preventing 
cancer progression, it would be recommended to study the efficacy of the 
optimised combination in an immunocompetent BALB/c mouse model. This 
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requires further in vitro studies on murine breast tumour cell line, 4T1, and 
injecting those cells into the mammary fat pads of those mice.  
ii. Currently, the published literature has suggested the short half-life of Rg3 
and in clinical trials, Rg3 is administered two times a day to overcome this 
issue. In the current study, the dosing schedule of the drug was limited to 
three doses per week. It is, therefore, recommended to use a more frequent 
dosing schedule of the drug to have a better estimation of the anti-cancer 
effects of this drug. 
iii. Further animal studies are suggested to evaluate the pharmacokinetic 
parameters of this drug. Using plasma of animals receiving this drug, not 
only the pharmacokinetics of the injectable form of the drug will be 
evaluated, but also the presence of metabolites will be measured. Based on 
the outcome of that study, it would be easier to predict and conduct more 
studies on the role of each of the Rg3 epimers, their metabolites, and the 
combination of those in the observed anti-cancer effects. 
iv. Administration of these drugs to mice, at the described dose and dosing 
schedule, caused no toxicity as recorded by weight score, posture, fur 
condition, movement, behaviour, breathing and hydration level. Rg3 has also 
been administered to humans with no serious reported toxicities. To further 
improve the preclinical studies on these drugs, animal toxicity assays will 
need to be performed. Several parameters such as type of drug formulation, 
dose, duration of exposure and route of administration affect the adverse 
effects. Subacute (14-28 days) and subchronic (90 days) animal toxicity 
testing including full biochemical and haematological screens and histology 
of the major organs should be performed to confirm the safety of the drugs 
prior to administration to humans. 
3. Designing novel formulations to improve the solubility and bioavailability 
of the drug: 
Ginsenosides have relatively large triterpenoid structures, with low water 
solubility and bioavailability. Therefore, the following are recommended: 
i. Structure-activity relationship (SAR) and quantitative SAR (QSAR) studies 
to be performed and evaluate the relationship between the chemical 
structure of these molecules and their biological activity. Therefore, 
potentially by modifying the structure, smaller molecules with better 
solubility and bioavailability could be designed and tested.  
ii. Novel pharmaceutical formulation modifications could be used to improve 
the solubility and bioavailability of these molecules. These modifications 
could include using nanosuspension and nanocrystal technologies or 
application of liposomes and cyclodextrins.  
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Overall, the findings of this thesis show the potential of the SRg3 and RRg3 optimised 
combination as an anti-cancer treatment for application in TNBC patients.  
